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1. Purinergic receptors 
1.1 Classification and basic structures 
Purinergic receptors were first recognized by Burnstock in 1978, when he 
proposed the two classes of purinoceptors termed P1 and P2 purinoceptors 
(Burnstock et al., 1978a;Burnstock et al., 1978b). P1 purinoceptors couple to 
adenylate cyclase and are competitively antagonized by low concentrations of 
methylxanthines. P2-puriniceptors are preferentially activated by ATP or ADP 
and other nucleotides. This agonist-based classification is the fundamental part of 
purinergic receptor research (Ziganshin et al., 2002). 
A1 and A2 subtypes in the adenosine/P1 receptor family were soon 
described by van Calker et al. in 1979 and Londos et al. in 1980 (Vancalker et al., 
1979;Londos et al., 1980). The stimulation of A1 and A2 receptors results in the 
inhibition and activation of adenylate cyclase, respectively. A2 receptors are 
further subdivided into A2A and A2B, with high- and low- affinity of A2 agonist, 
respectively. A3 receptor was later proposed following its cloning from rat 
striatum (Zhou et al., 1992). 
P2 purinoceptors are broadly subdivided into P2X and P2Y based on 
pharmacological characteristics in that α, β-meATP was the most potent agonist 
for the P2X purinoceptors, and 2-meSATP for P2Y purinoceptors (Burnstock & 
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Kennedy, 1985). ATP acts as a ligand for P2X purinoceptors and opens a cation 
selective channel (ionotropic receptors). ATP or UTP serves as a ligand for P2Y 
purinoceptors and causes the activation of the phosphoinositide signaling cascade, 
i.e. formation of inositol (1, 4, 5) triphosphate and release of Ca
2+
 from 
intracellular stores (metabotropic receptors).  
The purinoceptors are further classified by molecular biology approach 
(Dubyak, 1991;Pirotton et al., 1991;Harden et al., 1995). Based on sequence 
homology seven subclasses of the P2X receptor family (P2X1-7) was reported. 
These subclasses have 30-40%  homology in their primary structure (Khakh et al., 
2001), but differ considerably in the length of their carboxy-termini ranging from 
as short as 30 and 48 amino acids for P2X6 and P2X1, respectively to as long as 
240 amino acids for P2X7 (North, 2002). The structural features are predicted 
from the amino acids sequences of the cloned P2X receptors. The P2X receptor 
subunits have two hydrophobic transmembrane domains with intra-cellular amino 
and carboxyl-termini and an ATP-binding pocket within the extracellular 
intervening hydrophilic loop. However, one subunit with two transmembrane 
domains alone is unlikely to form an ion channel. They are organized in a homo 
or hetero-trimeric or larger complexes (Cusack, 1993a;Nicke et al., 1998). The 
extracellular loop of the seven receptors (P2X1 to P2X7) comprises of 10 
conserved cysteine residues, 14 conserved glycine residues, and 2-6 potential N-
linked glycosylation sites. The 10 cysteines form 5 disulfide bridges and impose 
structural constraints needed to couple the ATP-binding site to the ion channel.  
Majority of the conserved region are in the extra-cellular loop with the 
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transmembrane domains being less conserved. P2X receptors can also be divided 
into two broad groups according to the speed of desensitization: one group (P2X1 
and P2X3) desensitize rapidly within 50-300 ms and another group (P2X2, P2X4, 
P2X5, P2X6, P2X7) slowly up to several seconds. The mechanism of P2X 
receptor desensitization is not completely understood. The interactions between 
the two transmembrane domains, but not the extracellular loop of the P2X1 
receptor, are required for the receptor desensitization. However, the 
desensitization for P2X3 is controlled by Ca
2+
-dependent calcineurin-mediated 
dephosphorylation involving N-terminal residues.    
P2Y recptor family consists of 8 members (P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11, P2Y12, P2Y13 and P2Y14), all of which are 7-transmembrane G-protein 
coupled receptors (Cusack, 1993a). The positively charged amino acid residues in 
transmembrane domains (residues III, VI and VII) are involved in the ligand 
binding by electrostatic interactions with the phosphates of ATP (von Kugelgen & 
Harden, 2011). Other P2Y receptors including P2Y3, P2Y7, P2Y8, P2Y9 and 
P2Y10, were found identical with other P2Y receptor proteins and only exists in 
non-mammalian species. These P2Y receptors are not able to activate 
phospholipase-C (PLC) or adenylate cyclase (AC). Therefore, these receptors 
were eventually removed from the P2Y purinoceptor family. The signaling 
pathway initiated through all P2Y receptors is the activation of PLC, leading to 
IP3 formation and Ca
2+
 mobilization. This stimulates a variety of signaling 




 channels. The second 
signaling pathway is the inhibition of adenylate cyclase in almost all P2Y 
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subtypes, except in P2Y11 which stimulates adenylate cyclase. ATP and UTP 
activate almost all P2Y with variable potency. For example the positively charged 
amino acids of the P2Y2 receptor in the transmembrane regions VI and VII 
contributes from part of the ATP or UTP binding sites (Garrand et al., 1995). 
P2Y2 receptor couples to Gi/o and Gq/11 and mediate phospholipid breakdown 
and IP3 generation as well as Ca
2+
 mobilization via PLCβ. Moreover, inhibition 
of adenylate cyclase by P2Y2 receptor has been shown in some cell system.  
1.2. Extracellular ATP and purinergic signaling 
Over the last two decades, a total of 19 different purinergic receptor 
subtypes (including 7 P2X receptors, 8 P2Y receptors, and 4 adenosine receptors) 
that can recognize extracellular ATP and adenosine have been cloned and 
characterized (Ralevic & Burnstock, 1998). In addition, several families of 
ectonucleotidases that hydrolyse ATP to ADP, AMP and adenosine have been 
found (Zimmermann, 2000). These distinct sets of purinergic receptors and 
ectonucleotidases are expressed on the cell surface of the different mammalian 
cells and regulate cellular activities through cell-type specific purinergic signaling 
systems (Burnstock, 2008;Corriden & Insel, 2010).  
Controlled ATP release from intact cells was first identified in neurons  
(Abbracchio et al., 2009). ATP is also released from non-neuronal cells through 
vesicular transport (Praetorius & Leipziger, 2009). Additional mechanisms for 
ATP release has been reported including release through stretch-activated 
channels, voltage-dependent and multi-channel anion transporter or permeases 
(Alawqati, 1995), cystic fibrosis transmembrane conductance regulator (CFTR) 
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(Braunstein et al., 2001), and P2X7 receptor associated connexin and pannexin 
hemichannels (Praetorius & Leipziger, 2009). ATP release from mouse neutrophil  
occurs through connexin-43 hemi channels (Eltzschig et al., 2006).  
Extracellular ATP has two fates before being degraded by the 
ectonucleotidases. The released ATP either acts on the purinoceptors of the same 
cell (autocrine) or the neighboring cells (paracrine). Autocrine signaling through 
the purinergic receptors regulates the neutrophil chemotaxis via ATP release from 
polarized neutrophil in response to chemotactic mediators (Chen et al., 2006). The  
activated T cells also induces the release of ATP through pannexin 1 channels. 
These hemichannels translocate with P2X receptors to the immune synapse, 
where they promote Ca
2+
 influx and cell activation through  autocrine purinergic 
signaling (Schenk et al., 2008;Yip et al., 2009). The activation of purinergic 
receptors in immune cells can elicit either positive or negative feedback 
mechanisms and thus tighly regulate immune responses.  
Paracrine purinergic signaling regulates a wide range of physiological 
process, including immune cell functions (Bours et al., 2006;Corriden & Insel, 
2010). ATP released from damaged or stressed host cells serves as an important 
function in the recognition of ‘danger signals’ and guides phagocytes to 
inflammatory sites. Thus promotes clearance of damaged and apoptotic cells 
(Elliott et al., 2009). In response to damage-associated molecular patterns 
(DAMPs) and pathogen-associated molecular patterns (PAMPs), activation of 
inflammasome and the subsequent release of interleukin-1β (IL-1β) require 
purinergic singnalling.  In the cytoplasm nucleotides are concentrated in the 
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micomolar or even millimolar level, while the extracellular concentration is 
extremely low, usually in the nanomolar range (Dubyak, 2002). ATP is rapidly 
released upon damage of plasma membrane and diffuses throughout the 
pericellular space and bind to specific receptors expressed by virtually all immune 
cells (Di Virgilio et al., 2001). Diffusion of nucleotides is drastically controlled 
via degradation by ecto-nucleotidases expressed on the plasma membranes of 
most cells. Rapid metabolism of extracellular ATP generates the anti-
inflammatory metabolite adenosine and terminates the alert-signal to a checkpoint 
(Ohta & Sitkovsky, 2001). 
2. P2X7 receptor 
2.1. Distribution 
P2X7 receptors are expressed on the cells of hematopoietic lineage. The 
distribution of P2X7 receptor has been studied by permeability and RT-PCR 
analysis in cultured monocytes/macrophages (Hickman et al., 1994), phagocytes 
(CoutinhoSilva et al., 1996), dendritic cells (Coutinho-Silva et al., 1999), T 
lymphocytes (Baricordi et al., 1996), B lymphocytes (Wiley et al., 1992), mast 
cells (Tatham & Lindau, 1990)  and eosinophils (Ferrari et al., 2000). In the 
central nervous system functional P2X7 receptors are localized on microglia, 
Schwann cells and astrocytes (Ferrari et al., 1996;Collo et al., 1997). In dorsal 
root ganglia, P2X7 receptor appears to be selectively localized on glia cells, but 
not neurons. P2X7 receptor has also been identified in fibroblasts (Ferrari et al., 
1996;Solini et al., 2000), endothelial cells (Ray et al., 2002) and epithelial cells 
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(Slater et al., 2000). Our laboratory has reported previously specific expression of 
P2X7 receptors in alveolar type I epithelial cells (AEC I) (Chen et al., 2004). 
2.2. Structure 
The cytolytic P2Z receptor previously described in mast cells, 
macrophages and lymphocytes was re-classified as the P2X7 receptor on the basis 
of homology with the 6 described members of P2X family of receptors. ATP-
sensitive P2X7 receptors are the latest cloned member of the P2X family. The 
P2X7 receptor, first cloned from rat brain and human monocytes, is the most 
disparate from other P2X subtypes, in terms of structure and function (Rassendren 
et al., 1997;Surprenant et al., 1996). 
The human P2X7 receptor gene comprises 13 exons and is located on 
chromosome 12q24.31. It is about 52 Kb long, and 23.7 Kb away from the P2X4 
gene (Buell et al., 1998). There are 32 non-synonymous, amino acid-altering 
single nucleotide polymorphisms (SNPs) currently documented for the P2X7 gene 
in dbSNP. However, none of these SNPs alters P2X7 receptor expression or 
function. There has been no report of other types of gene mutations, such as 
deletion or splicing variants of mRNA, in P2X7 receptor. 
As other P2X receptor member, the P2X7 receptor has two 
transmembrane domains with intracellular amino and carboxy termini. 
Oligomeric structure in the plasma membrane is formed by trimerization or larger 
complexes of identical subunits. The P2X7 receptor appear not to form hetero-
oligomers with other P2X receptors (Kim et al., 2001). The unique feature of 
native P2X7 receptor is that it has a longer intracellular C-terminus (240 amino 
8 
 
acids) and forms pore in the plasma membrane. At least 177 amino acids take part 
in the pore formation (Surprenant et al., 1996). Two lysine residues in the 
extracellular loop of P2X7 receptor (K193 and K311) are considered important 
for ATP binding (Worthington et al., 2002). Alanine substitution of these residues 
abolished both BzATP and ATP- induced pore formation independent of the 
surface expression. A potential lipopolysaccharide (LPS)-binding motif (573-
CRWRIRKEFPKSEGQYSG) has been found at the end of the C-terminus of the 
P2X7 receptor (Denlinger et al., 2001). P2X7 receptor has also been shown to 
couple with extracellular matrix protein laminin α3, 3 cytoskeletal proteins (β-
actin, α-actinin4 and supevillin), an integrin subunit (β2), a scaffolding protein 
(MAGuK, membrane-associated guanylate kinase P55 subfamily member 3), 
three chaperones (heat shock protein 90 ‘hsp 90’, heat shock protein 70 ‘HSP 70’ 
and heat shock cognate 71,’Hsc 71’) and two signaling molecules (protein 
tyrosine phosphatase β ‘RPTPβ’ and phosphatidylinositol 4-kinase ‘PI4K’) (Kim 
et al., 2001). However, the exact role of these components to the phosphorylation, 
glycosylation, trafficking, membrane expression and function of P2X7 receptor is 
still unknown and needs further investigation. 
2.3 Pharmacology 
The non-desensitizing P2X7 purinoceptor is the most sensitive to steric 
aspects of ATP structure among all P2X receptors (Cusack, 1993b). The active 
agonist requires the adenine base, D-ribose sugar and the 5’-triphosphate side 
chain. 2’, 3’-O-(4-benzoylbenzoyl)-ATP (BzATP), a photoactivatable ATP 
analogue, is 10-100 times more potent than ATP in activating both native and 
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cloned P2X7 receptors (Dubyak & Elmoatassim, 1993). BzATP has significant 
greater potency (EC50= 20 µM) than ATP (EC50 > 100 µM). The rank order of 
agonist potency of ATP and its analogues for P2X7 receptors is 
BzATP>ATP>>2-meSATP>ATPγS (Gargett et al., 1997) and differs from other 
P2X receptors (Surprenant, 1996;Wiley et al., 1998). However, species 
differences between human and murine P2X7 receptors have been observed, 
based on different sensitivities to membrane permeabilzation by ATP, BzATP and 
ATPγS (Hickman et al., 1994). Brief agonist activation (< 10 s) of the P2X7 







permeability (Surprenant, 1996). Under the conditions of hypoxia or 
tissue injury, ATP is released into the extracellular spaces (North, 2002). 
Therefore, in metabolically compromised tissues extracellular Na
+
 is replaced by 
K
+
 and enhances the efficacy and potency of ATP on P2X7 receptors. K
+
 efflux 
enhances the ATP effect on P2X7 receptor–expressing cells. Thus, even low 
concentrations of ATP may activate the P2X7 receptor to a substantial extent 





 as well as fluorescent intercalator dyes such as YO-PRO-1 (375 
Da), ethidium
+
 (314 Da) are also permeable (Wiley et al., 1998). BzATP-
stimulated pore dilation and YO-PRO-1 dye uptake is one of the unique features 
of P2X7 receptors under physiological conditions. P2X7 receptor-mediated YO-
PRO-1 uptake does not occur in all cell types and is dependent upon receptor 
density (North, 2002). P2X7 receptor upon priming undergoes agonist plasticity 
such that brief agonist exposure resulting in an apparent increase in potency to 
10 
 
subsequent agonist exposure (Chakfe et al., 2002). However, prolonged P2X7 
receptor activation triggers a series of cellular responses, such as activation of 
caspases, cytokine release, cell proliferation and apoptosis (Panenka et al., 
2001;Perregaux et al., 2000). 
Novel series of P2X7 receptor antagonists, composed of cyclic imides have 
been shown to be effective in inhibiting P2X7 receptor (Stokes et al., 2006). For 
example, the cyclic imide member of this family, AZ10606120, potently blocks 
human P2X7 receptor-mediated cation influx and interleukin-1β (IL-1β) release. 
The AZD9056, have been shown to be effective against patients with chronic 
obstructive pulmonary disease (Stockley et al., 2008). The 2’, 3’-dialdehyde 
derivative of ATP, also known as oxidized ATP (OxATP), reacts with lysine 
residues at the ATP binding site to form a covalent schiff base. The reaction with 
OxATP gives total and irreversible inhibition of P2X7 receptor on mouse 
macrophages without affecting P2Y receptors (Murgia et al., 1993). OxATP are 
20-500-fold more potent for P2X7 receptor in human than that in mouse. 
However, OxATP has many other pharmacological off-targets including P2X1 
and P2X2 receptors (Evans et al., 1995) and nuclear factor-κB (NF-κB) and also 
inhibits cytokine release (Beigi et al., 2003). The isoquinoline sulfonamide 
derivative KN-62, a potent inhibitor of calcium and calmodulin-dependent kinase 
II (CaMKII), also acts on P2X7 receptor (Gargett & Wiley, 1997). Brilliant Blue 
G selectively blocks ATP-gated rat and human P2X7 receptors with IC50 of 10 
and 200 nM, respectively (Jiang et al., 2000). All three of these noncompetitive 
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antagonists, KN-62, OxATP and BBG are highly selective for P2X7 receptors, 
with different potency at P2X7 orthologs. 
2.4. Functions 
Activation of P2X7 receptor results in a rapid but reversible channel 






 ions. Recent 
evidence suggests that channel opening is distinct from the P2X7 receptor-
mediated pore formation. Firstly, the truncation of C-terminus (from residue 413) 
of rat P2X7 receptor results in loss of YO-PRO-1 uptake, but not BzATP-induced 
current, suggesting the long C-terminus is required for pore formation 
(Surprenant, 1996). Secondly, extracellular calmidazolium inhibits the BzATP-
induced current by up to 90%, but has no effect on YO-PRO-1 uptake, indicating 
that blockade of the ionic channel does not prevent the pore formation (Virginio 
et al., 1997). Thirdly, pore formation but not the ion channel opening is 
temperature-dependent (Nuttle et al., 1993). However, a number of signaling 
events have been demonstrated to follow the primary signal events (ionic channel 
opening/pore formation) following ATP activation of P2X7 receptor. 
2.4.1. Mature IL-1β, IL-18 and Nitric Oxide release 
IL-1β and IL-18 are pro-inflammatory cytokines that requires processing 
by interleukin converting enzyme (ICE, also known as caspase-1) at specific 
aspartic residues for mature molecule production. Activation of P2X7 receptor on 
human macrophages triggers the release of these two cytokines (Ferrari et al., 
1997a;Mehta et al., 2001;Perregaux et al., 2000). P2X7 receptor is also required 
for inflammasome assembly and caspase activation (Perregaux & Gabel, 1998). 
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Studies on P2X7 receptor knock-out mice have shown that absence of P2X7 
receptor leads to an inability to release IL-1β in response to ATP stimulation from 
peritoneal macrophages (Solle et al., 2001). P2X7 null mice therefore have 
impaired cytokine signaling cascade in vivo. This suggests that P2X7 receptor 
activation provides signals for maturation and release of IL-1β and initiation of a 
cytokine cascade.  
Both ATP and BzATP show a concentration-dependent stimulation of LPS-
stimulated nitric oxide (NO) release in macrophages. This effect is blocked by 
OxATP, strongly suggesting that P2X7 receptor plays a crucial role in LPS-
dependent NO release in macrophages (Sperlagh et al., 1998). Furthermore, LPS-
induced endogenous ATP release from macrophages could be the major source of 
ATP which activates P2X7 receptor in macrophages. 
2.4.2. Activation of NF-κB and Phospholipase D (PLD) 
ATP and BzATP can induce activation of a transcription factor controlling 
cytokine expression and apoptosis. This delayed ATP-effect is blocked by 
OxATP, indicating the involvement of P2X7 receptor. ATP induced-activation 
requires both reactive oxygen intermediates (ROIs) and caspase-1. The unique 
NF-κB-DNA complex induced by ATP is transcriptionally active and induces 
expression of NF-κB target genes (Ferrari et al., 1997b). This suggests that P2X7 
receptor control the expression of subsets of NF-κB target gene distinct from the 
classical proinflammatory mediators. 
Membrane phospholipase D (PLD) catalyses the phosphotidylcholine 





dependent and -independent phospholipase D activity following brief exposure in 
macrophages and lymphocytes. Stimulation of Ca
2+
-dependent PLD is directly 
proportional to bivalent cation influx through P2X7 receptor (Elmoatassim & 
Dubyak, 1993;Fernando et al., 1999).  
2.4.3. Cell membrane blebbing 
BzATP stimulation of HEK293 cells transfecteed with P2X7 receptor 
shows an irreversible loss of plasma membrane. This phenomenon does not occur 
in P2X2 receptor transfected cells. The unprocessed and mature form of IL-1β 
was found in the shed microvesicles (MacKenzie et al., 2001). P2X7–mediated 
microvesicle formation and shedding might be a crucial pathway for secretory 
protein release from cytoplasm. 
2.4.4. Shedding of L-selectin and CD23 
L-selectin (CD62L; a C-type lectin) and CD23 (low affinity IgE receptor) 
are involved in the adhesive interaction and rolling behavior of lymphocytes on 
endothelial cells (Gu et al., 1998). P2X7 receptor contributes to the regulation of 
intercellular interactions and to the generation of soluble markers. Elevated levels 
of CD62L and CD23 in sera have been reported from B-cell chronic lymphocytic 
leukaemia (B-CLL) patients (Wiley et al., 2002). ATP-induced shedding process 
of these molecules are metalloproteinase-mediated (Gu et al., 1998;Jamieson et 
al., 1996). ATP-induced L-selectins and CD23 shedding have also been shown to 
decrease in P2X7 receptor knock-out mice, indicating the pathophysiological role 




2.4.5. ATP-induced cytotoxicity 
Involvement of P2X7 receptor in ATP-induced apoptosis is well 
documented in lymphocytes (Chused et al., 1996), monocytes (Grahames et al., 
1999), macrophages (Blanchard et al., 1991), murine thymocytes (Pizzo et al., 
1992), and dendritic cells (Coutinho-Silva et al., 1999). P2X7 receptor activation 
has been shown to stimulate the activity of intracellular caspases prior to ATP-
induced apoptosis. K
+
 efflux through the P2X7 receptor ion channel leads to cell 
shrinkage and activation of caspase cascades (Bortner et al., 1997). 
2.5. Diseases 
P2X7 receptor plays important roles in immunity, inflammation, bone 
homeostasis, neurological function and neoplasia (Di Virgilio et al., 1998;Hughes 
et al., 2007). There is increase body of evidence implicating P2X7 receptor in 
various pathological conditions of pulmonary, cardiac, renal, skeletal muscle and 
central nervous system (CNS) disorders, where inflammation is the corner stone 
of these disorders. 
Studies in animal models have implicated a close connection of P2X7 
receptor to Alzheimer disease (McLarnon & Ryu, 2009), Parkinson’s disease 
(Takenouchi et al., 2010), multiple sclerosis, sensory neuropathies and 
neuropathic pain (Abbracchio et al., 2009). P2X7 receptor with its direct effect in 
apoptosis plays significant role as it was shown in prostate cancers (Maianski et 




P2X7 receptors are expressed in cells of the cardiovascular system and 
have been shown to be associated with hypertensions and thrombotic events 
(Furlan-Freguia et al., 2011). Production of cytokines and apoptosis of endothelial 
cells are critical phenomenon during vascular remodeling in hypertension. The 
hypotensive responses in inflammatory diseases via IL-1β release with nitric 
oxide synthesis are linked to P2X7 receptor function in the pathogenesis of 
cardiac disorders. 
The involvement of P2X7 receptor in the pathogenesis of pulmonary 
emphysema (Lucattelli et al., 2011), and COPD (Eltom et al., 2011;Cicko et al., 
2010) has been well documented. Pulmonary fibrosis is characterized by 
inflammation and fibrosis of the interstitium and destruction of alveolar 
histoarchitecture. Recent animal studies have identified the importance of P2X7 
receptor and pannexin-1 complex in IL-1β maturation, inflammation and 
evolution to pulmonary fibrosis (Riteau et al., 2010). 
3. Lung surfactant secretion 
3.1. Lung surfactant 
Lung surfactant is a lipid-enriched substance comprising of 80% 
glycerophospholipids, 10% cholestrol and about 5-10% proteins. Di-
palmitoylphosphatidyl choline (DPPC) is the major glycerophospholipid present 
in surfactant. The major function of surfactant is to reduce surface tension in the 
lung. There are 4 major surfactant proteins. SP-B and SP-C are synthesized in 
endoplasmic reticulumn and further processed by Golgi apparatus. These proteins 
are stored in lamellar bodies preceeding exocytosis (Clark et al., 1995). However, 
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SP-A and SP-D secretes constitutively independent of lamellar bodies (Rooney, 
2001). Alveolar epithelial type II cells (AEC II) stores and secrete surfactant. 
Physiologically, mechanical stretch, labor, and ventilation induce surfactant 
secretion from AEC II. However, recent experiments suggests that lung 
distensions rather than systemic changes accompanying hyperventilation (Pco2, 
Po2, and pH) increases surfactant secretion (Tschumperlin & Margulies, 1999). 
The mechanical stretch of the AEC II during an enhanced inspiration (‘sigh’) is a 
direct stimulus for surfactant secretion.  
3.2. Regulation of surfactant secretion  
The commonly held view of regulated surfactant secretion from AEC II 
involves cell membrane receptors including β2-adrenergic, adenosine A2B, and 
purinergic P2Y2. ATP, UTP, adenosine, platelet activating factor, LPS, and IL-1β 
are the known agonists to stimulate surfactant secretion (Andreeva et al., 2007). 
Stimulation of these receptors ultimately leads to activation of protein kinase A 
(PKA), protein kinase C (PKC) and calcium and calmodulin kinase (CaMK) and 
their downstream partners. The purinergic metabotropic receptor, P2Y2, is 
coupled to the G protein Gq, which stimulates phospholipase C (PLC) and 
hydrolyzes phosphotidylinositol biphosphate into diacylglycerol (DAG) and 
inositol triphosphate (IP3) (Rooney et al., 1992). The increase in intracellular Ca
2+
 
concentration results in enhanced surfactant secretion (Ashino et al., 2000). 
Surfactant exocytosis in AEC II is extremely sensitive to perturbations of Ca
2+
. In 
vitro, secretagogues including β2-adrenergic agonists (terbutaline), A2B receptor 
agonists (adenosine), P2Y2 receptor agonists (ATP and UTP), PKC activators 
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(phorbol esters) and calcium ionophores (A23187) have been shown to stimulate 
surfactant exocytosis. Terbutaline and adenosine activate adenyl cyclase which 
further stimulates PKA-mediated signaling. Moreover, ATP and phorbol esters 
activate PKC and downstream signaling molecules. The ionophores increase the 
intracellular calcium concentrations which further activates PKC and CAMK II. 
Activation of various kinases leads to phosphorylation of various proteins 
resulting in surfactant exocytosis. However, the mechanism of how the 
phosphorylation induces secretion is incompletely understood. 
3.3. Contribution of AEC I to surfactant secretion 
The alveolar epithelium has two specialized epithelial cell types: the 
terminally differentiated squamous AEC I and the surfactant producing cuboidal 
AEC II. The AEC I cover 95% of the alveolar surface and form a tight epithelial 
barrier with the AEC II to facilitate gas and water exchange. Alveolar epithelial 
cells are closely associated with endothelial cells, stromal fibroblasts, 
inflammatory cells, and the accompanying extracellular matrix. The function of 
AEC I has been relatively unexplored because it has been extremely difficult to 
isolate and culture viable AEC I (Williams, 2003). Our lab and other labs have 
developed methods to isolate AEC I (Williams, 2003;Wang & Hubmayr, 
2011;Chen et al., 2005). 
AEC I respond to the forces generated by mechanical ventilation i.e. 
conversion of physical forces on the cell membranes and/or receptors into 
activation of intracellular signaling pathway leading to Ca
2+
 wave generation. The 
intracellular Ca
2+ 
contributes to integrate signaling in lung epithelium. The 
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mechanisms underlying the coordination of intracellular Ca
2+
 changes in AEC I to 
neighboring AEC II involve diffusion of ions/second messenger molecules 
through gap junctions and release of ATP or UTP in the extracellular spaces. This 
subsequently activates Ca
2+
 signaling pathways in AEC II through purinergic 
receptors and induces surfactant release. Recent studies using the in situ technique 
confirm that calcium waves passed from AEC I to AEC II result in the release of 
surfactant from AEC II (Ashino et al., 2000). Mechanical stimulation of AEC I-
like cells in heterocellular culture propagated calcium to neighboring AEC II-like 
cells mainly via an apyrase-sensitive mechanism, suggesting that ATP is an 
extracellular mediator of alveolar cell communications (Boitano et al., 
2004;Isakson et al., 2003). ATP is produced by AEC I in response to mechanical 
stimulation and in turn triggers surfactant secretion from AEC II (Patel et al., 
2005). However, the mechanism of ATP release from AEC I has not been 
established. 
3.4. Mechanism of surfactant secretion 
 The regulated surfactant secretion is a slow and multiphasic process. 
Surfactant secretion consists of two phases, a prefusion and a postfusion phase, 
and is clearly separated in time (Dietl & Haller, 2005). The prefusion steps 
include transport of lamellar body to the plasma membrane and docking followed 
by a postfusion phase of fusion pore formation in the plasma membrane (Lindau 
& Gomperts, 1991). Surfactant exocytosis involves interaction of proteins present 
on the lamellar bodies and plasma membrane. During membrane fusion, the 
proteins residing on vesicle or v-SNAREs (on lamellar bodies in AEC II) interact 
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with those on plasma or target membrane to form a highly stable coiled-coil 
ternary SNARE complex (Chander et al., 2006). The coil is contributed by 
proteins including VAMP, syntaxin and SNAP proteins. Previously, from our lab 
we have reported the membrane fusion machinery of AEC II such as t-SNAREs 
syntaxin-2, SNAP-23, and annexin A2 (Abonyo et al., 2004;Wang et al., 2007). 
In vitro the formation of SNARE complex is sufficient for the close apposition 
and membrane fusion.  
 The vesicular contents of the lamellar body are released through fusion 
pore formation in the AEC II plasma membrane. The half time for the secretion of 
lung surfactant and its removal from the alveolar space in normal rat is 
approximately 4-10 hour (King & Martin, 1980;Young et al., 1981). However, in 
vivo surfactant release through fusion pores, permeation and spreading are more 
rapid than in vitro. Albeit the fusion of lamellar body with the plasma membrane 
occurs rapidly, the delivery of lamellar body contents to air-liquid interface is 
considerably slower.  
4. Acute Lung Injury 
Acute Respiratory Disease Syndrome (ARDS) is acute lung injury (ALI) 
of the alveolar/capillary membrane. ARDS is characterized by permeability 
pulmonary edema (fluid in the alveolar space) and acute respiratory failure. It is 
defined as acute respiratory distress with diffuse alveolar infiltrates on chest X-
ray, severe hypoxemia (PaO2/FIO2 <200). The etiology of ARDS includes 
aspiration of gastric contents, pneumonia, smoke inhalation, sepsis, trauma, drug 
overdose, multiple transfusions, pancreatitis, and venous air embolism. Sepsis is 
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an important predisposing factor, present in 40% of ARDS patients. Multiple risk 
factors increase the chance of developing ARDS.  
ALI is a common complication of mechanical ventilated patients and often 
synergized the upshots with sepsis background. Mechanical ventilation augments 
the acute lung injury caused by bacterial products. The molecular pathogenesis of 
this synergistic interaction per se remains incompletely understood hitherto. 
Mechanical stretch on alveolar walls produce several different consequences in 
injured lungs including the physical shear of alveolar epithelial and endothelial 
cells, disruption of the alveolar basement membrane, and activation of stretch-
responsive receptors and signaling pathways. A range of bacterial products 
activates a series of Toll like receptors, which induces ROS generation through 
oxidized phospholipids (OxPAPC) and increase in microvascular permeability. 
Thus, innate immune mechanisms are likely activated in the lungs of most 
patients before and after the onset of ALI. Alveolar cells produce a range of 
proinflammatory cytokines when exposed to bacterial products. Importantly, ATP 
is a potent candidate to activate the innate immune response. There is a significant 
degree of purinergic interplay in the prognosis of the ALI pathogenecity. 
The cardinal pathological findings in the lungs of patients with ALI were 
best described in a classic study in 1977 (Bachofen & Weibel, 1977). The 
pathogenesis of the disease can be inferred by concentering on the factors that are 
responsible for the accumulation of protein-rich and neutrophillic pulmonary 
edema in the lung and, the mechanisms that impair the removal of pulmonary 
edema fluid. Inflammatory cells from the lung are the inciting factors in the 
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pathogenesis of ALI. The protein –rich edema fluid in ALI is associated with 
large numbers of neutrophils, denuded alveolar epithelial cells and 
proinflammatory markers including cytokines, oxidants procoagulant factors and 
proteases. 
The initial cause of ALI is the lung vascular injury. An increase in lung 
vascular permeability occurs primarily at the level of lung microcirculation, 
which in turn results in the accumulation of protein-rich pulmonary edema fluid, 
even in the presence of normal lung vascular pressure (Brigham & Staub, 1998). 
A sustained loss of normal endothelial barrier function is best described in 
neutrophil-dependent lung injury (Matthay & Zimmerman, 2005). Neutrophil 
sequestration and activation in the lung microvasculature leads to degranulation 
and release of several toxic mediators, including ROS, proinflammatory cytokines 
and procoagulant molecules, resulting in increase of vascular permeability. 
Alveolar epithelial injury is another cardinal characteristic of ALI. 
Although the mechanisms responsible for epithelial injury in ALI are poorly 
understood, it appears that neutrophil and their products are primarily responsible 
for the increased paracellular alveolar permeability in ALI. However, neutrophil 
can cross the alveolar epithelium without affecting the lung epithelial 
permeability (Martin et al., 1989;Wienerkronish et al., 1991). In pathological 
states the migration of a large number of neutrophils results in increased epithelial 
injury (Downey et al., 1993). Furthermore, the degree of neutrophil activation 
(priming) by exposure to chemokines and other proinflammatory cytokines seems 
to play a crucial role in the alveolar epithelial injury as neutrophils crawl into the 
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distal airspaces. Transepithelial migration of neutrophils into the distal airspaces 
involves three distinct and sequential steps of adhesion, migration and post-
migration. Neutrophils adhere to the basolateral epithelial surface by β2-integrins 
(Folkesson & Matthay, 1997;Gao et al., 2001). The initial adhesion of neutrophils 
to the basolateral surface is primarily mediated by CD11b/CD18 molecules 
(Parkos et al., 1991). However, CD18-independent transmigration of neutrophils 
has also been documented. The paracellular route of neutrophil migration to the 
distal airspaces is also associated with CD47, a cell-surface molecule expressed 
on epithelial cells and neutrophils (Su et al., 2008). Once they traverse the 
epithelium and enter the airspaces, neutrophils adhere to the apical surface, where 
they phagocytize and kill bacteria. The release of toxic intracellular molecules 
from activated neutrophils induces dissolution of tight junction and necrosis of 
AEC I. Finally, apoptosis and phagocytosis of inflammatory cells are critical for 
the resolution of inflammation and mitigation of lung tissue damage. 
5. VCAM-1 
5.1. Biology 
Vascular cell adhesion molecule-1 (VCAM-1) is a type1 membrane 
glycoprotein belonging to the immunoglobulin (Ig) superfamily of cell adhesion 
molecules. The long isoform of VCAM-1 is a 110 kDa protein containing a 674-
amino acid extracellular domain organized into seven C2-type Ig domains, a 22-
amino acid transmembrane domain and a 19-amino acid cytoplasmic domain. The 
short isoform is a 45 kDa glycophosphatidylinositol (GPI)-linked protein 
containing the first three amino- terminal Ig domains of the transmembrane 
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isoform. Both the transmembrane and the GPI-anchored VCAM-1 isoforms can 
be released from cells to yield soluble VCAM-1 (sVCAM-1) that is detectable in 
serum and other body fluids. VCAM-1 expression has been reported on 
inflammed vascular endothelium by a number of stimuli (Carter & Wicks, 2001). 
VCAM-1 is also expressed on non-vascular cells, including dendritic cell in 
lymphoid tissues and skin, tissue macrophages, fibroblast (Meng et al., 1995), 
smooth muscle cells (Ardehali et al., 1995), bone marrow stromal cells 
(Feuerbach & Feyen, 1997), liver kupffer cells (van Oosten et al., 1995), renal 
tubular epithelial cells (Oertli et al., 1998) and lung epithelial cells (Popper et al., 
2002).  
The counter-ligands for VCAM-1 are heterodimeric α4 or α9-integrins 
noncovalently linked to either β1 or β7 chain (Newham et al., 1997;Feng et al., 
2000). Previous studies have shown the expression of functional α4-integrin in 
activated neutrophils which roll and adhere on VCAM-1 substrate, independent of 
selectins and β2-integrin (Ibbotson et al., 2001). The essential interactions 
between circulating neutrophil and activated endothelium permit effective egress 
of the neutrophil to the site of infection. The binding of the VCAM-1 to integrins 
allows tight association and diapedesis preceding initial events of rolling and lose 
tethering. Nevertheless, neutrophils in the lungs adhere to capillaries where the 
shear forces are greatly reduced. α4β1-integrin mediated tethering and adhesion is 




5.2. Contribution of sVCAM-1 in inflammation 
sVCAM-1 has been shown to mediate angiogenesis and is chemotactic to 
T-lymphocytes and monocytes (Tokuhira et al., 2000). sVCAM-1 levels are 
correlated with various diseases. Elevated sVCAM-1 levels have been 
documented in synovial fluids (SF) from patients with rheumatoid arthritis (RA) 
(Navarro-Hernandez et al., 2009), cerebrospinal fluid of patients with active 
multiple sclerosis (Rieckmann et al., 2005), serum from patients with advanced 
cancers (Okugawa et al., 2009), and inflammatory bowel disease and type II 
diabetes (Magro et al., 2004;Nakamura et al., 2008), alveolar lining fluid from 
pneumonia and asthma patients(Janson et al., 2005;Matsuno et al., 2007). 
  VCAM-1 shedding from transmembrane has been studied extensively in 
different cell systems. Regulated ectodomain shedding of VCAM-1 is cell 
specific (Rose et al., 2000) and involves mainly proteases from activated 
endothelium, epithelium, macrophages and/or neutrophils (Garton et al., 
2003;Redondo-Munoz et al., 2008). The proteolytic release of sVCAM-1 is 
mediated by the zinc metalloproteases of the type I transmembrane protein 
ADAM17 (TNFα-conveting enzyme; TACE) from stimulated endothelial cells, 
and elastase and cathepsin G released from activated neutrophils (Scheller et al., 
2011). The proteolytic cleavage by ADAM17 can be regulated by transactivation 
of the G-protein coupled receptors (GPCR). Phosphorylation of the cytoplasmic 
domain of ADAM17, stimulation-dependent internalization, partitioning of the 
ADAM17 and its substrates within lipid raft microdomains and regulated 
intramembrane proteolysis contributes to ectodomain shedding of VCAM-1 
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(Levine, 2008). Thus, sVCAM-1 resembles an important regulatory component of 
the inflammatory response. 
6. Objectives 
The present study was designed to elucidate the role of P2X7 receptor in 
AEC I and AEC II communications to surfactant exocytosis. The role of P2X7 
receptor in AEC I was studied for the regulation of surfactant secretion. The 
signaling pathway coupling AEC I and AEC II in surfactant release was further 
studied using different selective inhibitors. Next, series of conditioned-media 
experiments using stably and endogenously expressing P2X7 receptor, 
respectively were performed for the surfactant secretion from AEC II. Selective 
knock-down experiment for P2X7 receptor was also performed. Physiological 
stimulus like hyperventilation was employed and compared between wild-type 
and P2X7 receptor knock-out mice to evaluate the function of P2X7 receptor in 
hyperventilation-induced surfactant increase. Additionally, the involvement of 
P2X7 receptor in the pathogenesis of ALI has also been studied. Employing an 
experimental strategy of clinically relevant two-hit model of LPS and mechanical 
ventilation, we tested this idea using P2X7 receptor knock-out mice and selective 
P2X7 receptor inhibitor. Finally, attempts were made to study the mechanism of 
P2X7 receptor-mediated signaling events in ALI. One of the identified proteins, 
the soluble form of VCAM-1 (sVCAM-1), was further studied for their role in 
neutrophil chemotaxis in ALI. The study hence would be the first of its kind to 









Figure 1.1. Proposed pathophysiological role of P2X7 receptor in the normal 
and injured alveolus.  
In the normal alveolus, activation of P2X7 receptor in AEC I cell surface leads to 
ATP release. ATP in the extracellular space activates neighboring AEC II and 
stimulates surfactant secretion through P2Y2 receptor signaling pathway. In the ALI, 
there is sloughing of both bronchial and alveolar epithelial cells, denuded alveolar 
basement membrane. Alveolar macrophages secrete cytokines; IL-1β, IL-6, and 
TNF-α, that act locally on AEC I. This increases the VCAM-1 expression in AEC I 
membrane. P2X7 receptor stimulation on AEC I modulate ADAM17 activity 
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through MAPK activation. ADAM17 shed VCAM-1 from the AEC I surface. 
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PURINERGIC P2X7 RECEPTOR REGULATES LUNG SURFACTANT SECRETION 




Alveolar epithelium is composed of alveolar epithelial type I (AEC I) and type II 
(AEC II) cells. AEC II secretes lung surfactant via exocytosis. The P2 purinergic 
receptor, P2X7 receptor (P2X7R) has been implicated in the regulation of synaptic 
transmission and inflammation. Here, we report that AEC I-specific P2X7R is a novel 
mediator for the paracrine regulation of surfactant secretion in AEC II. In primary culture 
of AEC I and AEC II, BzATP, an agonist of P2X7R, increased surfactant secretion, which 
was blocked by the P2X7R antagonist, Brilliant Blue G. This effect was observed in AEC 
II co-cultured with the HEK293 cells stably expressing rat P2X7R, but not with the 
P2X7R knocked down AEC I or in isolated AEC I and AEC II from P2X7R
-/-
 mice. 
BzATP-mediated secretion involved P2Y2 receptor signaling since it was reduced by the 
addition of the ATP scavengers, apyrase and adenosine deaminase and the P2Y2 receptor 
antagonist, suramin. P2X7R
-/-
 mice failed to increase surfactant secretion in response to 
hyperventilation, pointing to the physiological relevance of P2X7R in maintaining 
surfactant homeostasis in the lung. These results suggest that the activation of P2X7R 
increases surfactant secretion by releasing ATP from AEC I and subsequently stimulating 
P2Y2 receptors in AEC II. 
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 Pulmonary surfactant, consisting of lipids and surfactant proteins, is synthesized 
and secreted by alveolar epithelial type II cells (AEC II). Surfactant secretion occurs 
through the fusion of the limiting membrane of lamellar bodies with the apical plasma 
membrane, followed by the extrusion of the lamellar body contents into the alveolar 
space.  Numerous surfactant secretagogues such as ATP, terbutaline, phorbol esters, 5’-(-
N-ethylcarboxamido) adenosine (NECA), vasopressin, and Ca
2+
 ionophores A23187 
augment surfactant secretion in cultured AEC II (Andreeva et al., 2007). These 
secretagogues initiate various signal transductions. For example, the stimulation of β2-
adrenergic receptors by terbutaline generates cAMP and activates protein kinase A 
(Dobbs and Mason, 1979), while the activation of purinergic P2Y2 receptors (P2Y2R) by 
ATP produces inositol triphosphate and diacylglycerol and activates protein kinase C 
(PKC) (Chander et al., 1995;Linke et al., 1997;Gobran and Rooney, 1999). 
Pulmonary alveoli are lined by thin, flat squamous alveolar type I cells (AEC I) 
interspersed in the alveolar epithelium. These cells form a nexus with cuboidal AEC II. 
AEC I have traditionally been thought to play a role in effective gaseous exchange. 
However, several new functions of AEC I have recently been uncovered including their 
role in protecting the lung from injury (Chen et al., 2006), and the regulation of alveolar 
fluid homeostasis (Johnson et al., 2006). 
Surfactant secretion alters with the spatiotemporal Ca
2+
 changes and signaling 
(Haller et al., 2001). Intracellular Ca
2+
 perturbation in AEC I and AEC II bipartitely 
communicates with each other via Ca
2+
 wave propagation through gap junctional 
intercellular communication or paracrine ATP release (Isakson et al., 2003;Patel et al., 
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2005). In situ fluorescence imaging has shown that interalveolar Ca
2+
 conductance 
initiates in AEC I and stimulates lamellar body extrusion from AEC II (Ichimura et al., 
2006). Moreover, Ca
2+ 
oscillations from AEC I communicate with AEC II during lung 
inflation, suggesting a role for AEC I in surfactant secretion (Ashino et al., 2000). 
However, the mediators for AEC I and AEC II communication are unclear. 
P2X7 receptor (P2X7R) belongs to the P2XR family. P2X7R has a significantly 
longer intracellular C-terminus where the last 177 amino acids are critical for the 
formation of the non-selective pore (North, 2002). Unlike other P2XRs, P2X7R only 





(Baraldi et al., 2004), and has a very low sensitivity to ATP (Young et al., 2007). The 
activation of P2X7R leads to the opening of a cationic channel with significant 
permeability to Ca
2+
 and intracellular depolarization (Rassendren et al., 1997;Virginio et 
al., 1997). The cation channel can convert to a non-selective pore permeable to small 
molecules and ions in the continued presence of ATP and low levels of divalent cations 
(North, 2002). The activation of P2X7R also results in the release of various cytokines 
and signaling molecules. These include ATP from astrocytes with the propagation of 
Ca
2+
 transmission (Suadicani et al., 2006a), interleukin-1 beta and matrix 
metalloproteinase-9 from immune cells as a pro-inflammatory response (Ferrari et al., 
2006;Gu and Wiley, 2006), prostaglandin from bone cells during osteogenesis (Li et al., 
2005) and neurotransmitters, GABA and glutamate from the hippocampus (Sperlagh et 
al., 2002). 
P2X7R is predominantly localized in immune cells, glial cells, hematopoietic cells 
and in various mammalian epithelial cells (Collo et al., 1997). P2X7R has been 
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implicated in inflammation (Hughes et al., 2007), periosteal and cancellous bone 
formation (Ke et al., 2003), apoptosis (Placido et al., 2006), Alzheimer Disease 
(Parvathenani et al., 2003) and autoimmune encephalomyelitis (Chen and Brosnan, 
2006). We have previously identified P2X7R as a specific marker of AEC I in the lung 
(Chen et al., 2004b). However, the functional role of P2X7R in the lung remains 
unexplored. In this study, using in vitro cell culture and in vivo P2X7R knock-out 
(P2X7R
-/-
) mice, we demonstrate that upon the activation of P2X7R, ATP is released from 
AEC I and modulates surfactant secretion in a paracrine manner via the P2Y2R and PKC-
mediated pathway. Our findings reveal a novel function of P2X7R in alveolar epithelial 









ATP (BzATP), Brilliant Blue G (BBG), adenosine 
deaminase (ADA), apyrase, suramin, staurosporine, ARL-67156, ATP bioluminescent 
assay kit (FLAA), polyclonal rabbit anti-P2X7 purinergic receptor, anti-purinergic 
receptor P2X7 (extracellular)-FITC and anti-podoplanin (anti-T1α) antibodies were 
obtained from Sigma (St. Louis, MO).  Elastase
 
was from Worthington Biochemical 
Corp. (Lakewood, NJ). Mouse anti-LB-180 (ABCA3) antibody was from Covance 
(Berkeley,
 
CA). Alexa 546- and 488-conjugated anti-rabbit and anti-mouse
 
secondary 
antibodies were from Molecular Probes (Eugene, OR).  Cy3-conjugated Affini-pure goat 
anti-mouse and anti-hamster IgG was from Jackson
 
ImmunoResearch Laboratories (West 
Grove, PA).  The Dc protein assay kit was from Bio-Rad (Hercules, CA). The enhanced 
chemiluminescence detection system was from Amersham
 
Biosciences (Piscataway, NJ).  
Anti-rat and anti-mouse IgG-conjugated magnetic
 
beads were from Dynal Biotech (Lake 
Success, NY).  Mouse anti-T1α antibody was a generous gift from Dr. Mary Williams 
(Boston University). Mouse anti-CD45 (anti-leukocyte common antigen or anti-LC) 
antibody was from BD Biosciences (Franklin Lakes, NJ). YOPRO-1 dye was from 
Invitrogen (Carlsbad, CA). Human embryonic kidney (HEK) 293 cells stably expressing 
rat P2X7R (HEK-P2X7R), E10 cells and R3/1 cells were kindly provided by Dr. 
Annmarie Surprenant (University of Manchester), Dr. Mary Williams (Boston 




2.3.2. Isolation of rat AEC I and AEC II 
Rat AEC I and AEC II were isolated from the lungs of pathogen-free male 
Sprague-Dawley
 
rats (150-200 gms) by modifying our previous method for isolating 
AEC I (Chen et al., 2004a), in which the elastase concentration was increased from 4.5 
U/ml to 8 U/ml. The Oklahoma State University Animal Care and Use Committee 
approved all the animal procedures used in this study. Rats were
 
anesthetized with an 
intraperitoneal injection of ketamine (40
 
mg/kg) and xylazine (8 mg/kg).  A tracheotomy 
was performed and rats were ventilated with a rodent ventilator throughout the process of 
perfusion.  The rats were exsanguinated via abdominal
 
aorta and heart transection.  A 







(0.9% NaCl, 0.1% glucose, 10 mM HEPES, pH 7.4, 5 mM KCl, 1.3 mM MgSO4, 1.7 
mM CaCl2, 0.1 mg/ml streptomycin sulfate, 0.06 mg/ml penicillin G, 3 mM Na2HPO4 
and 3 mM NaH2PO4), followed by instilling solution I (solution II plus 0.06 mg/ml 
EGTA) through the trachea. Lungs were removed and lavaged with solution I. The lungs 
were then digested by instilling warm elastase three times (8 U/ml in solution II, 7 ml) for 
20 min each at 37ºC to release AEC I and AEC II. The lung tissue was chopped and the 
cell suspension was mixed with 100 µg/ml DNase I and incubated for 5 min at 37ºC with 
gentle rotation. The cell suspension was then filtered through 160- and 37-µm nylon 
meshes once, followed by a 15-µm nylon mesh twice.  The cells were incubated in rat 
IgG-coated 100 mm polystyrene bacteriological Petri dishes (3 mg IgG/dish for each rat) 
at 37ºC for 45 min. The unattached cells were centrifuged at 250 xg for 10 min and 
resuspended with 1 ml of solution III (RPMI 1640 medium containing 25 mM HEPES 
and 1% FBS). 
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 To further remove the remaining leukocytes, the cells were resuspended in 0.5 ml 
Solution III and incubated with rat IgG (1 mg/ml) and anti-LC (16 µg/ml) at 4°C for 20 
min with gentle rotation. After being washed with solution III twice, the cells were 
incubated with sheep anti-rat IgG (150 µl/rat) and goat anti-mouse IgG (150 µl/rat) 
Dynabeads at 4°C for 15 min. A magnetic field was applied
 
to remove the cells attached 
to the magnetic beads. Finally, the cells were harvested and resuspended in DMEM 
containing 10% FBS, 0.1 mM nonessential amino acids,
 
1000 units/ml penicillin G and 
100 µg/ml streptomycin and cultured overnight for further experiments. The viabilities of
 
the cell preparations were determined by the Trypan blue dye exclusion method. 
2.3.3. Isolation of mouse AEC I and AEC II 
Mouse AEC I and AEC II were isolated from male C57BL/6 mice (6-8 wks of 
age) according to the previously reported procedure with some modification (Bortnick 
et al., 2003). Mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 
mg/kg). The abdominal cavity was opened, exsanguinated and cannulated with a 20 
gauge luer stub adapter through intratracheal route. Lungs were perfused with solution 
II, followed by instilling 1 ml of the digestion cocktail (dispase, 2500 caseinolytic 
units/ml and elastase, 4 U/ml in solution II) directly through the trachea. Three lungs 
were isolated, pooled into a beaker containing ~17 ml of the digestion cocktail and 
incubated at 37
o
C for 15 min. After incubation, the lungs were chopped. Lung tissues 
were further digested with the addition of DNase I (100 µg/ml) for 45 min at 37
o
C with 
intermittent shaking. The digested lungs were filtered through 160-, 37- and 15-µm 
nylon mesh sequentially. The filtrate was centrifuged at 250 xg for 10 min. The cell 
pellet was resuspended in DMEM media and incubated in a 100 mm petridish coated 
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with mouse IgG (75 µg/dish) for 1 hr. The cells were spun down at 250 xg for 10 min 
and resuspended in DMEM containing 10% FBS. The cell yield was ~8 x10
6
 per mouse 
and the cell viability was >95%.  
2.3.4. Immunocytochemistry 
Freshly isolated AEC I and AEC II were fixed with 4% paraformaldehyde for 30 
min, followed by cytospining them onto glass slides at 600 xg for 10 min. For overnight-
cultured cells, the cells were cultured on coverslips overnight and washed 3 times with 
phosphate-buffered saline (pH 7.4) prior to fixation with 4% paraformaldehyde for 30 
min. Cells were permeablized with 0.1% Triton X-100 for 15 min and blocked with 5% 
FBS for 1 hr.  Cells were incubated with mouse monoclonal anti-ABCA3 (1:200), anti-
T1α (E11, 1:100), and anti-CD45 (1:100) antibodies, and rabbit polyclonal anti-P2X7R 
(1:100) antibodies overnight at 4ºC. Cells were then washed and incubated with
 
Alexa 
546-conjugated anti-rabbit and Alexa 488-conjugated
 
anti-mouse secondary antibodies or 
Cy-3-conjugated
 
Affini-Pure anti-mouse IgG (1:250). 4'-6-Diamidino-2-phenylindole 
(DAPI, 2.5 mg/ml) staining was used for counting cells. Cells were viewed on a Nikon
 
Eclipse E600 fluorescence microscope or Nikon Eclipse TE 2000
 
U inverted fluorescence 
microscope.  
2.3.5. Cytometry 
Cytometry of isolated AEC I and AEC II was done by resuspending cells in the 
staining buffer (Hank’s balanced salt solution without phenol red plus 1% bovine serum 
albumin and 0.1% sodium azide) containing 10 µl P2X7R (ecto)-FITC antibody per 10
6
 
cells and incubated for 20 min at 4ºC with constant rotation. The cells were then washed 
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twice with the staining buffer and gated for P2X7R (ecto)-FITC-positive cells in a single 
argon laser cytofluorometer FACSCalibur (BD Biosciences). 
2.3.6. FM1-43 staining 
Fusion pore formation was monitored by FM1-43 staining as previously described 
(Chintagari et al., 2006). Overnight-cultured AEC I and AEC II were pre-incubated with 
100 nM BBG for 30 min and then stimulated for 1 hr with 25 µM BzATP. FM1-43 dye 
(4 µM final concentration) was added along with BzATP. Cells were washed, fixed with 
4% ice-cold paraformaldehyde and examined with a fluorescence microscopy. 
2.3.7. YOPRO-1 Dye uptake 
Accumulation of the monomeric cyanine nucleic acid chelating dye, YOPRO-1 
(MW 375 Da) was used as an indicator of the P2X7R activation (Stokes et al., 2006). 
Freshly isolated AEC I and AEC II or cell lines (E10, R3/1 and HEK-P2X7R cells) (1 x 
10
6
/ml) were incubated with the assay buffer containing 15 mM HEPES, pH 7.4, 135 
mM NaCl, 5 mM KCl, 1.8 mM CaCl2 and 0.8 mM MgCl2 in the presence or absence of 
100 nM BBG for 20 min. YOPRO-1 at a 5 µM final concentration was added and 
incubated for additional 5 min. The cells were transferred to a cuvette under continuous 
stirring, and YO-PRO-1 fluorescence was measured by a FluoroMax-3 spectrofluorimeter 
(HORIBA Jobin Yvon, Edison, NJ) using an excitation and emission wavelength of 491 
nm and 509 nm, respectively.  BzATP (200 µM) was added after recording the baseline 
for 3-4 min.  Fluorescence intensity was corrected with the cells without dye. In some 
cases, baselines were adjusted for comparisons between the different cells. 
 Dye uptake was also monitored directly by a fluorescence microscopy in order to 
assess the P2X7R activation in a specific type of cells of the AEC I and AEC II 
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heterocellular culture. Overnight-cultured cells were washed twice and incubated with the 
assay buffer for 15 min.  BzATP (200 µM) was added and incubated with YOPRO-1 (5 
µM) for 20 min. Cells were then incubated with Nile red (10 µM) for an additional 2 min, 
washed twice with PBS, fixed with 4% ice-cold paraformaldehyde and examined with a 
fluorescence microscopy. 
2.3.8. Surfactant secretion assay 
Surfactant secretion was performed as previously described (Chintagari et al., 
2006). The freshly isolated AEC I and AEC II (1 X 10
6 
in a 35 cm dish for rat and 0.8 x 
10
6





 cells). The heterocellular culture was incubated with or without 
various inhibitors or antagonists for 30 min. One set of the dishes were removed at this 
time point for analyzing the time zero value. The cells were then incubated with BzATP 
or other secretagogues for 2 hrs. At the end of incubation, lipids in the medium and cells 
were extracted using a one-step phosphotidylcholine extraction method (Vassar et al., 
2007). The radioactivities were counted. Surfactant secretion (%) was expressed as (dpm 
in medium/dpm in medium and cells) x100. All of the secretion data was corrected by 
substracting the time zero value. A stimulation index was defined as a ratio of stimulated 
secretion to basal secretion.    
2.3.9. MTT assay 
Cell viability was assessed using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide (MTT) dye conversion or Trypan blue exclusion assays as described 




2.3.10. Western blot 
Cells were lysed in lysis buffer (10 mM Tris-HCl,
 
pH 7.5, 1% Triton X-100, 1 
mM EDTA, 1 mM phenylmethylsulfonyl
 
fluoride, 10 µg/ml aprotonin and 10 µg/ml 
leupeptin).  The protein concentration was determined by the Dc protein assay
 
kit. Protein 
was separated on a 10% SDS-polyacrylamide
 
gel and transferred to a nitrocellulose 
membrane. The membrane
 
was stained with Ponceau S to ensure proper transfer and 
blocked
 
overnight with 5% dry skim milk in 100 mM Tris-buffered
 
saline plus 0.1% 




antibodies at a 
1:1000 dilution or anti-β actin antibodies at a 1:2000 dilution overnight at 4°C. After 
being
 
washed with TBST three times, the membranes were incubated with horseradish
 
peroxidase-conjugated anti-rabbit IgG (1:2000)
 
for 1 hr.  The blots were washed again 
and individual target
 




HEK 293 cells stably expressing rat P2X7R (HEK P2X7R) and HEK 293 cells 
were cultured in a DMEM and F12 (1:1) medium containing 10% FBS, 2 mM glutamine,
 
1000 units/ml penicillin G, and 100 µg/ml streptomycin. E10 and R3/1 cells were 
cultured in CMRL and F12-HAM’s media containing 10% FBS, 2 mM glutamine, 1000 
units/ml penicillin G and 100 µg/ml streptomycin, respectively.  All the cells were grown 
to confluence, released and co-cultured with freshly isolated AEC II in a 1:2 ratio in 
DMEM media for 16-18 hrs.  Cells were labeled and assayed for surfactant secretion as 
described above. The radioactive counts in E10, R3/1, HEK-P2X7R and HEK 293 cells 
were less than 10% of that in AEC II. 
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To determine the effects of conditioned media on surfactant secretion, E10 cells, 
HEK-P2X7R and HEK 293 cells were grown to confluence in the respective culture 
media as described above. Freshly isolated AEC II was cultured for 16 -18 hrs in DMEM 
complete media. These cells were washed three times with DMEM and incubated with 
100 µM ARL-67156 and 25 µM BzATP for 2 hrs. The conditioned media was removed 
and centrifuged at 250 xg for 5 min. The supernatant was transferred to recipient 
[
3
H]choline-labeled AEC II. Cells were further incubated for 2 hrs and surfactant 
secretion was assayed. 
2.3.12. Measurement of ATP concentration 
The cells were washed three times with 1 ml of DMEM and pre-incubated with or 
without 100 nM BBG for 15 min. BzATP (25 µM) was added to stimulate the cells for 10 
min. The media were removed to avoid the interference of BzATP for ATP assay. The 
fresh medium containing 100 µM ARL-67156 was added and incubated for 20 min. 
Media were centrifuged at 600 xg for 10 min. Supernatant was collected and frozen in 
aliquots at -20ºC for subsequent ATP assay. 
 ATP concentration was measured using the chemiluminescent luciferin-luciferase 
assay kit. Media (25 µl) were placed in a white opaque 96 well plate. An equal volume of 
luciferin-luciferase assay solution was added to each well. Luminescence was recorded 
using a FLUOSTAR microplate reader (BMG, Labtech, Germany). Luminescence 
measurements were taken for 5 min with an integration time of 60 ms/well.  A stardand 
curve was generated for each experiment with ATP standards up to 1 µM. The results 




2.3.13. Knock-down of P2X7R 
 Adenoviral shRNA vectors were construced as prevously described (Gou et al., 
2007).Two shRNA sequences targting to 574-592 and 669-689 of mouse P2X7R were 
chosen (Jun et al., 2007;Lu et al., 2007) and was named as si-X7 (1) and si-X7 (2). E10 
cells were transduced with virus control, si-X7 (1) and si-X7 (2) for 4 days at a MOI of 0-
100.  
2.3.14. Preloading assay for dye transfer  
This was done according to the methodology described by Koval M  et al. 
(Abraham et al., 2001). E10 cells cultured  in  35 mm  tissue culture dishes were 
incubated with DMEM containing  1 mg /ml  of Texas Red Dextran (10,000 mw) and 10 
µM  calcein-AM  for 30 min at 37ºC. Freshly isolated unlabeled acceptor AEC II were 
co-cultured with the double-labeled E10 cells for 5 hrs and fluorescence images were 
taken.  
2.3.15. Real-time PCR 
Real-time PCR analysis was performed as previously described (Jin et al., 2006). 
The primers used were listed in Table 3. Data were normalized to 18S rRNA. 
2.3.16. Surfactant secertion in mice 
 Surfactant secretion in wild-type and P2X7R
-/-
 mice was measured according to 
the method of Ikegmai et al. (Ikegami et al., 2000). P2X7R
-/-
 mice on a C57BL/6 
background were purchased from the Jackson Laboratory (strain: B6.129P2-
P2rx7
tm1Gab
/J) and bred in the Laboratory Animal Resources Unit at Oklahoma State 
University. The wild-type (C57BL/6) and P2X7R
-/-
 mice were given intraperitoneally 0.5 
µCi[
3
H] choline/g body weight and housed for 16 hrs. The mice were hyperventilated for 
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30 min with a tidal volume (Vt) of 30 ml/kg and a positive end-expiratory pressure 
(PEEP) of 5 cm H2O as described (Wyszogrodski et al., 1975). Under these conditions, 
surfactant secretion was increased and the inactivation of surfactant did not occur because 
of the use of positive end-expiratory pressure (Wyszogrodski et al., 1975). The mice were 
killed. The lavage and lung tissue were collected. Lipids were extracted and saturated 
phosphatidylcholine isolated according to the method of Mason et al. (Mason et al., 
1976). Secretion was expressed as (dpm in lavage)/(dpm in lavage and lung tissue) x 
100%. 
2.3.17. Statistical Analysis 
Data was expressed as means ± SE.  Statistical analysis was performed by one-
way analysis of variance, followed by Tukey’s Analysis or student’s t test using 




2.4.1 Characterization of a heterocellular culture of AEC I and AEC II 
To study the communication of AEC I and AEC II, we first developed a new 
heterocellular culture of AEC I and AEC II. A mixed preparation of AEC I and AEC II 
was isolated from rat lungs based on the method modified from the AEC I isolation 
(Chen et al., 2004a). The cell viability was ~97% and the cell yield was ~54 x 10
6
/rat. 
Immunophenotyping using specific cell markers revealed that the freshly isolated cells 
contained ~31% AEC I and ~64% AEC II (Table 2.1). This ratio is similar to the AEC I 
and AEC II numbers in vivo. FACS analysis confirmed that 34% of AEC I existed in the 
mixed cell preparation. Macrophage contamination was ~3%. Overnight-cultured cells 
also showed a positive staining of T1α (AEC I marker) and ABCA3 (AEC II marker) 
(Figure 2.1A). AEC I displayed the characteristic squamous morphology with the 
retracted accordion-like appearance of long cytoplasmic extensions (Figure 2.1C).  The 
ratio of AEC I and AEC II was essentially the same as that of the freshly isolated cells 
(Table 2.1). These results suggest that AEC I and AEC II maintain their phenotypes after 
overnight culture.  Double-labeling demonstrated that P2X7R was only present in AEC I, 
but not in AEC II (Figure 2.1B), confirming the specific localization of P2X7R in AEC I 





Figure 2.1: Identification of AEC I and AEC II in heterocellular culture.  
(A) Overnight cultured cells were double-labeled with polyclonal rabbit anti-T1α (AEC I 
marker, green) and monoclonal mouse anti-ABCA3 (AEC II marker, red). (B) Overnight 
cultured cells were double-labeled with polyclonal rabbit anti-P2X7R (red) and 
monoclonal mouse anti-ABCA3 (green) antibodies. (C) Enlarged images showing AEC I 
characteristics labeled with AEC I specific monoclonal mouse anti-T1α. Arrows indicate 




Table 2.1 Characterization of AEC I and AEC II preparations  
 
 
Freshly isolated (D0) or overnight-cultured (D1) AEC I and AEC II were identified with 
anti-T1α and anti-ABCA3 antibodies, respectively. Macrophages were determined using 
mouse anti-CD 45. The cells were counted from 10 randomly selected fields of each cell 
preparation. The percentages of cell populations were calculated (means ± SE, n=5 
independent cell preparations). *Data were obtained from flow cytometry analysis of 
AEC I labeled with FITC-P2X7R (n=2). Cell viability was determined by the trypan blue 
dye exclusion method.  
  
 
AEC I       
(%) 












D0 31.4 ± 1.9 
*34.1 ±0.3 
63.6 ± 2.2 2.9 ± 0.5 1.9 ± 0.3 54 ± 2 97 ± 3 
D1 28.6 ± 1.9 63.6 ± 1.1 4.4 ± 0.9 3.9 ± 1.1 
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2.4.2 The activation of P2X7R in AEC I 
We next determined whether P2X7R can be activated in AEC I of the 
heterocellular culture of AEC I and AEC II. The activation of P2X7R leads to the opening 
of non-selective pores that are permeable to small molecules (<900 Da) including YO-
PRO-1. The accumulation of the monomeric cyanine nucleic acid chelating dye, YO-
PRO-1 has been used as an indicator of the P2X7R activation (Stokes et al., 2006). The 
overnight cultured cells were incubated with YO-PRO-1 in the presence of 2’, 3’-O-(4-
benzoyl-benzoyl) ATP (BzATP), a specific agonist of P2X7R.  Nile red was used to 
identify AEC II (Chen et al., 2004a).  As shown in Figure 2.2A, the cells that did not 
have the Nile red staining took up the dye, indicating the activation of P2X7R in AEC I. 
To quantitate the dye uptake, the cells were incubated with YO-PRO-1 for 5 min and 
YO-PRO-1 fluorescence was measured by spectrofluorimeter. BzATP caused a rapid 
increase of the intensity in heterocellular AEC I and AEC II preparation, but had no 
effects on AEC II alone (Figure 2.2B). Brilliant Blue G (BBG) inhibits rat P2X7R at 100 
nM and does not affect other P2X receptors even at >10 µM (Jiang et al., 2000). The 








Figure 2.2: BzATP specifically increased YO-PRO-1 uptake in AEC I.  
(A) Overnight-cultured AEC I and AEC II were incubated with 5 µM YO-PRO-1 in the 
absence (control) or the presence of 200 µM BzATP for 20 min, followed by incubation 
with 10 µM Nile red. The cells were fixed and examined with a fluorescence microscope. 
Arrows point to AEC I. Scale bar: 40 µm. (B) AEC I and AEC II mixture or AEC II 
alone were incubated with 5 µM YO-PRO-1 for 5 min in the absence or presence of 100 
nM BBG. The basal line was recorded with Ex=491 nm and Em=509 nm and 100 µM 
BzATP was added at 4 min. The fluorescence intensities were corrected with the cells 





2.4.3 BzATP stimulates surfactant secretion in a heterocellular culture of AEC I and 
AEC II  
To determine the functional role of P2X7R in surfactant secretion, we stimulated 
the heterocellular culture of AEC I and AEC II with BzATP and assessed the changes in 
surfactant secretion. BzATP increased surfactant secretion in a dose-dependent manner 
with an EC50 of 4.5 ± 0.3 µM. However, BzATP had little effect when AEC II were 
seeded alone (Figure 2.3A). BBG abolished the BzATP-mediated surfactant secretion 
(Figure 2.3B). BBG was specific to P2X7R since BBG did not affect surfactant secretion 
induced by other lung surfactant secretagogues including ATP, terbutaline and PMA 
(Figure 2.3C). The cell viability was unchanged by BzATP or BBG as seen by MTT 
assay (data not shown). BzATP also increased the fusion pore formation as determined 
by FM1-43 staining (Chintagari et al., 2006), which was blocked by BBG (Figure 2.4). 






Figure 2.3: Effect of BzATP on surfactant secretion in a heterocellular culture.  
Freshly isolated AEC I and AEC II or AEC II alone were incubated with [
3
H] choline 
overnight. (A) The cells were stimulated with various concentrations of BzATP for 2 hrs. 
(B) AEC I and AEC II were pre-treated for 0.5 hr with 10 nM or 100 nM BBG and then 
incubated with 25 µM BzATP for 2 hrs. (C) AEC I and AEC II were pre-treated with 100 
nM BBG for 30 min and then stimulated with 1 mM ATP or 0.1 µM terbutaline plus 1 
µM PMA for 2 hrs. Surfactant secretion was measured by monitoring the release of [
3
H]-
labeled PC. The results were expressed as a stimulation index (a ratio of surfactant 
secretion in stimulated cells over those in unstimulated cells). Data shown are means ± 
SE. In (A), *P < 0.01 v.s. unstimulated cells (n=3-7, One way ANOVA and Tukey’s 
multiple comparison). In (B), *P<0.0001 v.s. control; **P<0.0001 v.s. BzATP, n=5, 






Figure 2.4: BzATP increases fusion pore formation.  
AEC I and AEC II were pre-treated with 100 nM BBG for 30 min and then stimulated 
with 25 µM BzATP in the presence of 4 µM FM1-43 dye for 1 hr. Cells were washed 
twice with PBS and fixed for fluorescence microscopy. Arrows point to AEC I. Scale 





2.4.4 Co-culture of AEC I-like cell line containing P2X7R with AEC II increases 
surfactant secretion 
P2X7R is highly expressed in the lung epithelial cell line, E10, but not in the R3/1 
cell line (Barth et al., 2007). Both cell lines have the properties similar to AEC I 
(Koslowski et al., 2004;Kathuria et al., 2007). We confirmed that E10 cells had very high 
expression of P2X7R and R3/1 cells expressed little P2X7R (Figure 2.5A). BzATP 
increased YOPRO-1 dye uptake in E10 cells, but not in R3/1 cells, indicating that P2X7R 
in E10 cells is functional (Figure 2.5B). We then co-cultured isolated AEC II with E10 or 
R3/1 cells in a ratio of 2:1 and examined the effects of the activation of P2X7R on 
surfactant secretion in this co-culture system. Upon BzATP stimulation, a significant 
increase in surfactant secretion from AEC II co-cultured with E10 cells was observed 
(Figure 2.5C). This increase in secretion was blocked when the cells were pre-treated 
with BBG. There was only a slight increase of surfactant secretion in the BzATP-





Figure 2.5: E10 cells expressing endogenous P2X7R increase surfactant secretion 
upon BzATP stimulation.  
(A) Expression of endogenous P2X7R in E10 and R3/1 cells. 30 µg of total cell lysates 
were probed with anti-P2X7R and anti-β-actin antibodies. (B) Accumulation of YOPRO-
1 dye. E10 and R3/1 cells were incubated with YOPRO-1 for 5 min and fluorescence was 
monitored. BzATP (200 µM) was added to initiate the reaction. Data are means ± SE 
(n=2). (C) AEC II were co-cultured with E10 or R3/1 cells overnight. The cells were then 
pre-treated with 100 nM BBG for 30 min and stimulated with 25 µM BzATP for 2 hrs. 
PC secretion was measured. The results were corrected by substracting that from E10 or 
R3/1 cells. Data are means ± SE (n=3 independent cell preparations). *P<0.001 v.s. 




2.4.5 Co-culture of HEK293 cells stably expressing P2X7R with AEC II increases 
surfactant secretion 
If P2X7R is the mediator for the communication between AEC I and AEC II, any 
cells that express a functional P2X7R should be able to replace AEC I. We thus utilized 
the HEK293 cells stably expressing rat P2X7R (HEK-P2X7R) (Jiang et al., 2000) for the 
co-culture experiment. HEK293 cells were used as a control. Western blot analysis 
showed that HEK-P2X7R expressed much higher P2X7R than HEK control cells (Figure 
2.6A). The ectopically expressed P2X7R was functional since BzATP markedly increased 
YOPRO-1 uptake in HEK-P2X7R in comparison with HEK (Figure 2.6B). In the co-
culture of HEK-P2X7R and AEC II, BzATP dramatically increased surfactant secretion 
(Figure 2.6C). This effect was abolished by BBG. No significant stimulation of surfactant 





Figure 2.6: HEK293 cells stably expressing rat P2X7R increase surfactant secretion 
upon BzATP stimulation.  
(A) Expression of recombinant rat P2X7R in HEK-P2X7R and HEK cells. Cell lysates (5 
µg) were probed with anti-P2X7R and anti-β-actin antibodies. (B) YOPRO-1 
accumulation. HEK-P2X7R and HEK cells were incubated with YOPRO-1 for 5 min and 
YOPRO-1 fluorescence was monitored. BzATP (200 µM) was added after 200 Sec. Data 
are means ± SE (n=2). (C) Surfactant secretion. AEC II were co-cultured with HEK-
P2X7R or HEK cells (2:1) overnight. The cells were pre-treated with 100 nM BBG for 30 
min and stimulated with 25 µM BzATP for 2 hrs. PC secretion was measured and 
corrected by substracting that from HEK-P2X7R or HEK alone. Data are means ± SE 




2.4.6 P2X7R-evoked AEC communication is a paracrine phenomenon 
 To determine whether P2X7R-mediated increase in surfactant secretion is via a 
paracrine stimulation or direct cell-cell contact, we examined the effects of conditioned 
media from the BzATP-stimulated E10 or HEK-P2X7R cells on surfactant secretion in 
AEC II. E10 or HEK-P2X7R cells were incubated with BzATP and ecto-ATPase 
inhibitor, ARL-67156 for 2 hrs. The conditioned media were then transferred to the 
recipient AEC II. The conditioned media from both E10 and HEK-P2X7R dramatically 
increased surfactant secretion by 9.5- and 7.2-fold, respectively (Figure 2.7A).  Under the 
same conditions, AEC II and HEK293 conditioned media showed no significant increases 
in surfactant secretion from AEC II.  
To further demonstrate that the observed effects are due to P2X7R receptors, we 
determined the effects of the conditioned media from the P2X7R knocked-down E10 cells 
on surfactant secretion from AEC II. E10 cells were transduced with an adenovirus 
carrying shRNA targeting to mouse P2X7R gene, 574-592 [si-X7 (1)] and 669-689 [si-X7 
(2)]. Both shRNAs resulted in reduction of P2X7R protein after a 4-day transduction 
(Figure 2.7B). The stimulatory effects on surfactant secretion by the conditioned media 
from the P2X7R knocked-down E10 cells decreased significantly in comparison with that 
from control virus-treated cells (Figure 2.7C).  
To further address the possible gap junction contribution to P2X7R-mediated 
surfactant secretion, we co-cultured freshly isolated type II cells and E10 cells in a ratio 
of 2:1. Using a preloading assay (Abraham et al., 2001), we observed gap junction 
formation between E10 cells and type II cells (Figure 2.7D). BzATP stimulated surfactant 
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secretion in this co-culture system. However, the gap junction blocker, β-glycyrrhetinic 









Figure 2.7: Effects of conditioned media from P2X7R-containing cells on surfactant 
secretion.  
(A) AEC II, E10 cells, HEK-P2X7R or HEK were incubated in the presence or absence of 
25 µM BzATP for 2 hrs. The conditioned media were collected and transferred to the 
recipient AEC II and incubated for additional 3 hrs. PC secretion was measured. Data are 
means ± SE of 3 independent experiments. *p<0.001 v.s. unstimulated E10 control cells, 
**p<0.01 v.s. HEK-P2X7R unstimulated control cells. (B) E10 cells were transduced with 
an adenovirus carrying irrelevant shRNA (VC), shRNA targeting to 574-592 [si-X7 (1)] 
or 669-680 [si-X7 (2)] of mouse P2X7R at a MOI of 50 or 100.  Un-treated cells were 
used as a blank control (BC). After 4 days, the cells were collected for Western blot 
analysis. (C) VC, si-X7 (1) or si-X7 (2)-treated E10 cells (4 days, MOI, 100) were 
incubated with 25 µM BzATP for 2 hrs. The conditioned media were added to type II 
cells. After 3 hrs, surfactant secretion was measured. *P<0.001 v.s. VC (n=3).  (D) 
Preloading assay for dye transfer. E10 cells were preloaded with Texas Red Dextran and 
calcein-AM and then co-cultured with freshly isolated AEC II for 5 hrs. The donor E10 
cells showed fluorescence in both Texas Red and Calcein. Arrows indicates the acceptor 
AEC II had only calcein fluorescence, indicating the formation of   functional gap 
junction between E10 cells and type II cells. (E) AEC II  and E10 cells were co-cultured 
(2:1 ratio) for 16 hrs and incubated with the gap junction blocker (GJB), 18-α-
glycerrhitinic acid (40 µM) for 30 min. Cells were further stimulated with 25 µM BzATP 
for additional 2 hrs. Surfactant secretion was measured by monitoring the release of [
3
H]-
labeled PC. The results were expressed as a stimulation index (a ratio of surfactant 
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2.4.7 ATP is responsible for the P2X7R-mediated surfactant secretion 
The activation of P2X7R results in ATP release from rat astrocytes (Suadicani et 
al., 2006a).  We therefore examined whether ATP is released from AEC I upon P2X7R 
activation of AEC I and AEC II culture. BzATP was able to evoke a robust induction of 
ATP release (74 ± 17 nmole/10 µg of total protein) in the heterocellular culture of AEC I 
and AEC II (Figure 2.8A). This release was blocked by pre-incubating the cells with 
BBG. BzATP did not cause any changes in ATP levels in bulk media of the AEC II 
monoculture. To determine whether ATP released from AEC I is responsible for the 
BzATP-mediated surfactant secretion, we used the nucleotide scavengers, apyrase and 
adenosine deaminase to remove ATP and measured surfactant secretion in the AEC I and 
AEC II heterocellular culture. Surfactant secretion caused by BzATP was reduced by 
apyrase and adenosine deaminase treatment (Figure 2.8B). These results collectively 
indicate that P2X7R activation releases ATP from AEC I, which in turn acts on AEC II to 






Figure 2.8: P2X7R evokes surfactant secretion through ATP release.  
(A) Effect of P2X7R modulation on ATP release. AEC I and AEC II were pre-incubated 
with 100 nM BBG for 30 min and stimulated with 25 µM BzATP or 5 min. The BzATP 
was removed and fresh medium was added and incubated for additional 10 min. At the 
end of incubation, media were collected and ATP was measured. The results were 
expressed as nmole ATP secreted into media over 10 min normalized to 10 µg of total 
protein. Data are means ± SE from 3 independent cell preparations. *P<0.05 v.s. control; 
**P<0.05 v.s. BzATP. (B) Effect of removal of ATP on surfactant secretion. AEC I and 
AEC II were incubated with adenosine deaminase (ADA, 5 U/ml) and apyrase (10 U/ml) 
for 30 min, followed by stimulation with 25 µM ATP for 2 hrs. Surfactant secretion was 
measured by monitoring the release of [
3
H]-labeled PC. Data are means ± SE. n=3-4. 




2.4.8 P2X7R-mediated surfactant secretion is via the P2Y2R signaling 
Since the activation of P2X7R releases ATP, we determined whether BzATP-
mediated surfactant secretion is due to the activation of the P2Y2R signaling. We 
measured surfactant secretion after blocking the P2Y2R signaling in the AEC I and AEC 
II heterocellular culture with suramin (an P2Y2R antagonist), BAPTA-AM (an 
intracellular Ca
2+
 chelator), and staurosporine (an PKC inhibitor). As shown in Figure 
2.9, the BzATP-evoked surfactant secretion was significantly inhibited by all of the 
agents. However, no significant decrease in secretion was observed in the presence of the 
PKA inhibitor, H89.  Taken together, these observations suggest that released ATP from 
AEC I acts through P2Y2R and PKC-dependent pathway to promote surfactant secretion 






Figure 2.9: Paracrine control of surfactant secretion is mediated via P2Y2R and 
PKC signaling pathway  
Overnight cultured AECI and AECII were pre-treated with suramin (100 µM), BAPTA-
AM (50 µM), staurosporine (100 nM) or H89 (50 nM) for 30 min, followed by 
stimulation with BzATP (25 µM). PC secretion was measured. Data are means ± SE of 3-




2.4.9 BzATP was not able to stimulate surfactant secretion in a heterocellular 
culture of AEC I and AEC II from P2X7R-/- mice. 
We isolated mouse AEC I and AEC II from C57BL/6 mice. The cell yield was 8.2 
± 1.3 x 10
6
 per mouse. Double labeling with anti-SP-C and T1α antibodies (Fig. 2.10A) 
revealed 57 ± 1% AEC II and 29 ± 1% AEC I (n=5). Yield, Purity and AECI-AECII ratio 
were not significantly different between wild-type and P2X7R
-/-
 mice. The known lung 
surfactant secretagogues (ATP, PMA and terbutaline) increased surfactant secretion by 
~3-fold in the AEC I and AEC II from wild-type mice (Figure 2.10B), which is higher 
than the isolated mouse AEC II alone (Rice et al., 2002;Gobran and Rooney, 
2004;Guttentag et al., 2005). BzATP also stimulated surfactant secretion and BBG 
blocked the BzATP effects in the wild-type mouse cells. Lung surfactant secretagogues 
markedly increased surfactant secretion from the P2X7R
-/-
 AEC I and AEC II 
heteroculture, indicating that AEC II respond to lung surfactant secretagogues normally. 
However, the AEC I and AEC II from P2X7R
-/-
 mice failed to respond to BzATP in 
surfactant secretion. These results further support our hypothesis that P2X7R is a 





Fig. 2.10: Effect of BzATP on surfactant secretion in type I and type II cell 
heteroculture from wild-type and P2X7R-/- mice.  
(A) Wild-type mouse type I and type II cells were double-labeled with mouse anti-
ABCA3 (type II cell, green) and hamster anti-T1α (type I cells, red). Scale bar, 40 µm. 
(B) The cells were cultured overnight and stimulated for 2 hrs with lung surfactant 
secretagogues (100 µM ATP, 0.1 µM PMA and 10 µM Terbutaline) or 25 µM BzATP 
plus or minus 100 nM BBG. Secretion was measured. Data shown are means ± SE (n=3 
independent cell preparations). *P<0.001 v.s. control; **P<0.001 v.s. BzATP. WT: wild-





2.4.10 Hyperventilation increases surfactant secretion in wild-type mice, but not in 
P2X7R-/- mice. 
 Hyperventilation has been shown to increase surfactant secretion (Oyarzun and 
Clements, 1978;Hildebran et al., 1981;Nicholas and Barr, 1983), possibly through 
mechanical stretch (Wirtz and Dobbs, 1990). Since P2X7R interacts with the proteins that 
are associated with mechanotransduction (Pavalko et al., 1998;Kim et al., 2001;von et 
al., 2003), we investigated potential defects in P2X7R
-/-
 mice in responses to 
hyperventilation. Western blot analysis confirmed the absence of P2X7R in the lungs of 
P2X7R
-/-
 mice (Figure 2.11A). Real-time PCR analysis revealed that P2X receptors, P2X2 
and P2X4 were increased several folds in P2X7R
-/-
 mice in comparison with wild-type 
mice (Figure 2.11B). P2X1, P2X3 and P2X6 receptors had a modest increase in the 
P2X7R
-/-
 mice. No changes were observed for P2X5 receptors. P2Y receptors were not 
significantly affected by P2X7R knock-out (Figure 2.11C). While SP-B increased about 
1-fold in the P2X7R
-/-
 mice, SP-A and SP-C were not changed (Figure 2.11D). T1 α, a 
type I cell marker was not different between wild-type and P2X7R
-/-
 mice.  
We also compared surfactant lipid secretion in whole animal between wild-type and 
P2X7R
-/- 
mice according to the method of Ikegami et al. (Ikegami et al., 2000). There was 
no significant difference in basal surfactant secretion between wild-type and P2X7R
-/-
 
mice. However, hyperventilation increased surfactant secretion in wild-type mice, but not 
in P2X7R
-/-
 mice (Figure 2.11E). No significant changes were observed in total cell 
counts and total proteins in lavage under all of the conditions (data not shown), indicating 





Fig. 2.11 Comparison of Surfactant secretion in P2X7R-/- and wild-type mice.  
(A) Western blot of lung tissues from wild-type and P2X7R
-/-
 mice. (B-D) Real-time PCR 
analysis of P2X receptors (B), P2Y receptors (C) and Surfactant protein (D). Data were 
normalized to 18S rRNA. *P<0.05 (n=3 animals, assayed in duplicate). (E) Surfactant 
secretion. Mice were intraperitoneally injected 0.5 µCi/gm [
3
H] choline and 
hyperventilated for 30 min. Lipids in lavage and lung tissue were extracted and saturated 
PC isolated. Surfactant secretion was calculated as a percentage of dpm in larvage over 













Gene               Forward primer sequence               Reverse primer sequence 
P2X1 TCAAGGACATTGTGCAGAGAAC  CAGTTGCCTGTGCGAATACCT  
P2X2 GCGTTCTGGGACTACGAGAC  ACGTACCACACGAAGTAAAGC  
P2X3 AAAGCTGGACCATTGGGATCA  CGTGTCCCGCACTTGGTAG  
P2X4 CTCGGGTCCTTCCTGTTCG  GTTTCCTGGTAGCCCTTTTCC  
P2X5 AGGGGGTGGCCTATACCAAC GGTTAGGAGTCACGATCAGGTT  
P2X6 GTTAAGGAGCTGGAGAACCG AGGATGCTCTGGACATCTGC  
P2X7 TGCATCACCACCTCCAAGCTCTTCCAT  CACCAGCAAGGGATCCTGGTAAAGC  
P2Y2 TGTGGCCAATCCTATTTCAATTT  CCACGAGCCCAGAAAAAAGA  
P2Y6 TGACCCGTTCCGCTGTGTAC  GCGCTGGAAGCTAATGCAGG 
P2Y12 ATGGATATGCCTGGTGTCAACA  AGCAATGGGAAGAGAACCTGG  
P2Y13 TGGGTGTTCGTCCACATCC  GCAAGGTGTGAGTCGGAAAG  
SP-A GAGGAGCTTCAGACTGCACTC AGACTTTATCCCCCACTGACAG 
SP-B CTGCTTCCTACCCTCTGCTG CTTGGCACAGGTCATTAGCTC 
SP-C ATGGACATGAGTAGCAAAGAGGT CACGATGAGAAGGCGTTTGAG 
18S  ATTGCTCAATCTCGGGTGGCTG CGTTCTTAGTTGGTGGAGCGATTTG 
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Hyperventilation causes mechanical stretch and alkalosis. To determine whether there is a 
difference in alkalosis between wild-type and P2X7R
-/-
 mice, we performed blood gas 
analysis. As shown in Table 2.3, hyperventilation did not causes significant changes in arterial 
blood oxygen (PaO2) level in wild-type and P2X7R
-/-
 mice. However, hyperventilation 
increased arterial blood pH and decreased arterial blood CO2 (PaCO2) in both wild-type and 
P2X7R
-/-
 mice. These results indicate that there were no significant differences in 
hyperventilation-induced alkalosis between wild-type and P2X7R
-/-
 mice. Data are Means ± 
S.E. (n=3 animals), *p < 0.05 v.s. corresponding non-ventilated control, One way ANOVA , 
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     7.46 ± 0.02 
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    33.56 ± 4.71 
 
 
    19.97 ± 1.53* 
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     155.78 ± 1.53 
 
 
     153.08 ± 3.70 
 
 
















Over the past few decades, substantial insights into mechanisms of surfactant 
synthesis and its release have been gained. However, the steps that control the regulation 
of this multifaceted event under physiological circumstances remain poorly understood. 
AEC I has been suggested as a potential contributor to the regulation of surfactant 
secretion in AEC II (Ashino et al., 2000;Isakson et al., 2003;Patel et al., 2005). However, 
what factors in AEC I mediate AEC I and AEC II communication are unknown. In the 
present study, we report that P2X7R in AEC I is responsible for the communication 
between AEC I and AEC II in the regulation of surfactant secretion. The results from this 
work shows that upon P2X7R activation, AEC I releases ATP, which acts on AEC II in a 
paracrine manner to trigger surfactant release via the P2Y2R and PKC pathway. 
The ensuing effort to understand the function of AEC I as a possible partner of 
AEC II largely depends upon the cell culture models. Due to the difficulty in isolating 
AEC I in high purity and yield, AEC I-like cells trans-differentiated from freshly isolated 
AEC II have been used to study the communication between AEC I and AEC II (Isakson 
et al., 2003;Patel et al., 2005). These AEC I-like cells may not represent the in vivo AEC 
I phenotype since DNA microarray analysis reveals a different set of gene expression 
between isolated AEC I and the AEC I-like cells (Gonzalez et al., 2005). In this study, we 
developed a heterocellular culture of AEC I and AEC II directly isolated from rat lungs. 
This system has a 1:2 ratio of AEC I and AEC II numbers that is similar to that of the in 
vivo lungs. Furthermore, the model maintains AEC I and AEC II phenotypes including 




Several lines of evidence support that the activation of P2X7R couples AEC I–
AEC II for the regulation of surfactant secretion. First of all, BzATP, an agonist of 
P2X7R, increased surfactant secretion and fusion pore formation in a hetercellular culture 
of AEC I and AEC II. The increase in surfactant secretion is due to specific activation of 
P2X7R in AEC I: (i) P2X7R is specifically expressed in AEC I, but not AEC II in intact 
lung tissue (Chen et al., 2004b) and in our heterocellular culture of AEC I and AEC II; 
(ii) BzATP specifically activated P2X7R in AEC I as determined by the YOPRO-1 dye 
uptake; (iii) BzATP did not affect surfactant secretion in AEC II alone, indicating that 
BzATP does not activate other receptors in AEC II; (iv) BBG, an antagonist of P2X7R 
blocked the BzATP-induced surfactant secretion. The specificity of BBG was 
demonstrated by its failure to inhibit other lung surfactant secretagogue-stimulated 
surfactant secretion including ATP, terbutaline and PMA in the hetercellular culture of 
AEC I and AEC II; (v) BzATP had no effects on surfactant secretion from AEC I and 
AEC II isolated from P2X7R
-/-
 mice. 
Another evidence for P2X7R as a mediator for the increase in surfactant secretion 
comes from co-culture of P2X7R-expressing cells with AEC II. Two lung cell lines, E10 
and R3/1 cells have AEC I properties (Koslowski et al., 2004;Kathuria et al., 2007). 
However, E10 cells express a high level of P2X7R, while R3/1 cells have little P2X7R 
(Barth et al., 2007). Thus, these cell lines provide a tool to investigate the effect of 
P2X7R on surfactant secretion in AEC II. Co-culture of E10 cells with AEC II results in a 
robust increase in surfactant secretion in response to BzATP stimulation, which was 
abolished in the presence of BBG. This increase in surfactant secretion was not observed 
when R3/1 cells were co-cultured with AEC II. E10 and R3/1 cells were established by a 
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clonal outgrowth of adult mouse lung tissue and explant-replica of the E20 fetal lungs of 
Han-Wistar rats, respectively. It is possible that the observed differences between E10 
and R3/1 cells are due to other properties of the cell lines rather than P2X7R. To 
eliminate this possibility, rat P2X7R was overepxressed in HEK 293 cells that do not 
express endogenous P2X7R and are not related to AEC I. The HEK 293 cells stably 
expressing P2X7R, but not the control HEK 293 cells, when co-cultured with AEC II, 
elicited a marked increase in surfactant secretion upon BzATP stimulation. Furthermore, 
knock-down of P2X7R in E10 cells abolished its stimulatory effects on surfactant 
secretion. These results suggest that P2X7R is one of the key components in AEC I that 
regulates surfactant secretion.  
The communication between AEC I and AEC II can be accomplished via two 
major routes: gap junction and paracrine communication (Koval, 2002). Gap junction 
channels are formed by the assembly of two hemichannels on two cells. Each 
hemichannel is composed of six connexins, a large family of transmembrane proteins. A 
gap junction channel allows the direct transmission of small signaling molecules and 
metabolites from one cell to another. AEC I and AEC II express different sets of 
connexins (Lee et al., 1997;Abraham et al., 1999;Isakson et al., 2003). Functional and 
heterotypic gap junction channels have been demonstrated between AEC I and AEC II, 
which involves at least one of the connexin, Cx43 (Abraham et al., 2001;Isakson et al., 
2003). In a heterocellular culture of AEC I-like and AEC II-like cells, mechanical 
stimulation of AEC I leads to Ca
2+
 wave propagation to AEC II via gap junctions 
(Isakson et al., 2001;Isakson et al., 2003). In situ fluorescence microscopic analysis of 





initiated on AEC I which are transmitted to AEC II by gap junctions (Ashino et al., 
2000). Paracrine cell-to-cell communication involves the release of soluble factors from 
one type of cells and the action on another. Stretch triggers ATP release from AEC I-like 
cells, which stimulate surfactant secretion when co-cultured with freshly isolated type II 
cells (Patel et al., 2005). However, in a heterocellular culture of AEC I-like and AEC II-
like cells, AEC II-like cells transmit Ca
2+
 signal to other cells via ATP release (Isakson et 
al., 2003).  
What are the mechanisms for P2X7R-mediated AEC I and AEC II 
communication? We can rule out cell-to-cell contact and/or gap junction as a major 
mechanism since the gap junction blocker, β-glycyrrhetinic acid did not block BzATP-
stimulated surfactant secretion. Furthermore, the conditioned media from the BzATP-
stimulated E10 or HEK-P2X7R cells had comparable stimulation of surfactant secretion 
as that in the co-culture of these cells with AEC II. Thus, the release of soluble factors 
from AEC I upon the activation of P2X7R is likely responsible for AEC I and AEC II 
communication. One such factor is ATP. Indeed, P2X7R activation in the heterocellular 
culture of AEC I and AEC II released ATP in the bulk milieu, which was blocked by 
BBG. This effect was completely absent in AEC II monoculture. There is evidence 
showing that P2X7R mediates ATP release in other cell systems (Arcuino et al., 
2002;Pellegatti et al., 2005;Suadicani et al., 2006b). The removal of ATP from the media 
nucleotide scavengers significantly inhibited the BzATP-stimulated surfactant secretion, 
further supporting that ATP released from AEC I upon the activation of P2X7R functions 
as a soluble mediator to enhance surfactant secretion. 
92 
 
Regulated surfactant secretion in AEC II responds to extracellular ATP 
stimulation through P2Y2R (Linke et al., 1997). The activation of P2Y2R in AEC II 
stimulates G-protein coupled phospholipase C, resulting in the generation of 
diacylglycerol and IP3 and the activation of PKC in a Ca
2+
-dependent manner (Chander et 
al., 1995). AEC II express several PKC isoforms (PKC- α, β1, β2, η, δ, µ and ξ) that 
potentiate protein phosphorylation and final fusion events (Gobran and Rooney, 1999). 
The blocking of P2Y2R by suramin, chelation of intracellular Ca
2+
 by BAPTA, and 
inhibition of PKC by staurosporine all abolished the BzATP-evoked increase in 
surfactant secretion in heterocellular culture of AEC I and AEC II. ATP can be degraded 
into adenosine (Fields and Burnstock, 2006), which can stimulate adenosine A2 
receptors,  activate PKA and increase surfactant secretion (Griese et al., 1991). However, 
the increase in surfactant secretion caused by BzATP was unaffected by the PKA 
inhibitor, H89, indicating that the PKA pathway is not involved in the P2X7R-mediated 
surfactant secretion. These results suggest that ATP released from AEC I upon the 
stimulation of P2X7R activates P2Y2R signaling in AEC II and thus increases surfactant 
secretion. Our results demonstrate for the first time purinergic signaling coupling 
between AEC I and AEC II for surfactant secretion regulation. 
The P2X7R
-/-
 mice are viable and fertile (Solle et al., 2001). However, some 
defects were observed. For example, although peritoneal macrophages from P2X7R
-/-
 and 
wild-type mice produce similar amounts of pro-IL-1β after LPS challenge, the 
macrophages from P2X7R
-/-
mice do not generate mature IL-1β in response to ATP (Solle 
et al., 2001). These mice also have a decreased periosteal bone formation and an 
increased resorption in trabecular bone tissue (Ke et al., 2003). The lack of P2X7R results 
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in a reduction of mechanical loading-stimulated bone growth (Li et al., 2005). However, 
no information on the lung phenotype is available in these mice. Our present studies 
showed that BzATP did not stimulate surfactant secretion in AEC I and AEC II isolated 
from P2X7R
-/-
 mice. Furthermore, when they were challenged with hyperventilation, 
wild-type mice showed an enhanced surfactant secretion, but P2X7R
-/-
 mice did not. 
Hyperventilation is known to increase surfactant secretion (Oyarzun and Clements, 
1978;Hildebran et al., 1981;Nicholas and Barr, 1983), likely via mechanical stretch 
(Wirtz and Dobbs, 1990). P2X7R is involved in mechanotransduction (Pavalko et al., 
1998;Kim et al., 2001;von et al., 2003). Thus, the lack of response to hyperventilation in 
P2X7R
-/-
 mice may be due to a defect in sensing mechanical stretch in type I cells via 
P2X7R.  
It has been suggested that ATP may play a role in asthma and chronic obstructive 
pulmonary diseases (COPD) (Adriaensen and Timmermans, 2004). Adenosine, a 
metabolite of ATP in alveolar lining fluid increases 2-3 fold in asthmatics and non-
symptomatic smokers in comparison with control subjects (60-70 µM). There is dys-
regulation of surfactant homeostasis in infant and acute respiratory distress syndrome 
(Gunther et al., 2001). Therefore, our finding of P2X7R-mediated ATP signaling 
transduction and surfactant secretion regulation adds a novel and attractive therapeutic 
intervention to control alveolar surfactant pool by modulating the endogenous surfactant 
system, eventually resulting in the treatment of pulmonary diseases with surfactant 
defects. 
  In conclusion, our results demonstrate that the activation of P2X7R possibly by 
mechanical stress releases ATP from AEC I and paracrinacally stimulates surfactant 
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secretion from AEC II via the P2Y2R and PKC-mediated signaling pathway (Figure 
2.12). This finding reveals a novel function of P2X7R in the lung by which AEC I 
communicates with AEC II via P2X7R, contributing to fine tuning of surfactant balance. 
The current studies also reinforce the idea that AEC I is not a simple barrier for gas 
exchange, but functional cells in the lung. Thus, it is imperative to further study P2X7R 
biology in alveolar epithelial cells in order to gain a better understanding of the cellular 
and molecular events of surfactant homeostasis, cell-cell communication and the 
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A CRITICAL ROLE OF P2X7 RECEPTOR-INDUCED VCAM-1 SHEDDING AND 




The trafficking of neutrophil to sites of injury is largely directed by signals from the 
epithelium, but how chemotactic gradients are formed is not known. Here we have 
demonstrated a novel mechanism by which P2X7 receptor (P2X7R) on type I alveolar 
epithelial cells (AEC I) regulates soluble VCAM-1 shedding that functions as a potent 
chemoattractant for neutrophil. Employing a clinically relevant two-hit model of 
mechanical ventilation (MV) and lipopolysachharide (LPS) we demonstrate that in the 
mice with P2X7R deficiency (P2X7R
-/-
) or selective inhibition of pulmonary P2X7R, 
infiltration of neutrophils in the bronchoalveolar lavage (BAL) was abrogated. This was 
accompanied by a reduction of sVCAM-1, IL-1β and IL-6 in BAL. Neutrophil 
infiltrations and pro-inflammatory cytokine release was also significantly reduced by 
functional antibody blocking of alveolar VCAM-1 activity. In contrast, recombinant 
VCAM-1 rescued the P2X7R
-/-
 phenotype. ADAM-17 from the AEC I surface cleaved 
IL-1β-stimulated VCAM-1 in a P2X7R-dependent manner. Neutrophil chemotaxis is 
directed predominantly towards soluble VCAM-1. Together, these findings suggest that 
soluble VCAM-1 shed from AEC I in injured alveoli functions as a competent 
chemoattractant for neutrophils. This is the first description of a new function of 
soluble VCAM-1 in the lung. Therapeutic interventions targeting P2X7R and VCAM-1 
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may provide a novel strategy to reduce neutrophil sequestration without altering yet 
critical mediators in lung injury. 
 





Acute lung injury is a progressive syndrome that develops directly from pneumonia, 
gastric acid aspiration, inhalation of toxic gases or indirectly from extra pulmonary sepsis 
or trauma. Among them sepsis-related clinical cases possess the highest risk of lung 
injury progression and associated mortality rates (Rubenfeld et al., 2005). At present, 
mechanical ventilation (MV) with a low tidal volume is the life-saving supportive therapy 
adopted in clinical practices of these critically ill patients (Chiumello & Cressoni, 
2009;Kallet et al., 2005).  
Alveolar epithelium provides the first line of defense against invading pathogens and 
produces a range of pro-inflammatory mediators including IL-1β, IL-6, TNF-α, KC, MIP-
2 and soluble forms of adhesion molecules (Skerrett et al., 2004a;Mendez et al., 2006). 
The release of soluble proteins from alveolar epithelium acts in consort to recruit and 
confine inflammatory cells to sites of injury. The regulatory mediators are operational 
when the inflammatory process is most likely to be reversible (Pittet et al., 1997). A well 
orchestrated series of events follow the rapid ingress of neutrophil in alveolar space with 
hemorrhage and protein–rich edema fluid accumulation, as an early consequence of 
capillary-alveolar barrier damage. Even though information has been accumulated in 
recent years on the sentinel events of neutrophil recruitment at the site of injury, therapy 
is limited because of incomplete understanding of the molecular mechanisms regulating 
these events. 
Vascular cell adhesion molecule 1 (VCAM-1) is a member of the immunoglobin 
supergene family and was colligated originally as an cytokine-inducible adhesion 
molecule on human endothelial cells (Osborn et al., 1989;Rice & Bevilacqua, 1989). The 
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membrane-bound form of VCAM-1 (a 110-kDa type-I transmembrane glycoprotein) is 
abundantly found on the surface of leukocytes (Walsh et al., 1996;Ibbotson et al., 
2001;Elices et al., 1990;Ruegg et al., 1992) and act as a counter ligand for the α4β1 (very 
late antigen-4 [VLA-4, CD49d/CD29]) and α4β7 (lymphocyte-Peyer’s patch adhesion 
molecule-1 [LPAM-1, CD49d/CD103]) integrins. The VCAM-1 expedites transmigration 
of α4 integrin–positive cells across the inflamed endothelium and epithelium in the lung 
(Chin et al., 1997;Parmley et al., 2007). VCAM-1 can be released into a soluble variant, 
sVCAM-1 by proteolytic cleavage (Garton et al., 2003). sVCAM-1 binds with α4β1 
integrins and mediates function ascribed to their transmembrane counterpart (Rose et al., 
2000;Nakao et al., 2003a). sVCAM-1 levels are correlated with various diseases. 
sVCAM-1 is elevated in synovial fluids from patients with rheumatoid arthritis 
(Wellicome et al., 1993), cerebrospinal fluid of patients with active multiple sclerosis 
(McDonnell et al., 1998), serum of patients with advanced cancers (Velikova et al., 
1998;Velikova et al., 1997), inflammatory bowel disease, and type I diabetes (Goke et 
al., 1997;Clausen et al., 2000), and alveolar lining fluid from pneumonia and asthma 
patients (Matsuno et al., 2007;Hamzaoui et al., 2001). 
The margination of neutrophil into the lung primarily sieve through narrow 
capillaries. However, in other organs like liver, kidney neutrophils are sequestered via 
post-capillary venules of systemic circulation (Erzurum et al., 1992;Downey et al., 1993). 
The essential firm adhesion between heterodimeric β2 integrins (CD18/αM) and/or CD11 
(CD11a,-b, -c, -d) on circulating neutrophils and ICAM-1 (CD54) on activated 
endothelial cells permit effective egress of neutrophils (Hogg & Walker, 1995). However, 
functional blockade of CD11/CD18-dependent adhesion pathways  only inhibits 60-80% 
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of neutrophil emigration in response to E.coli lipopolysachharide (LPS), Pseudomonas 
aeruginosa or IL-1β, alluding the importance of CD18-independent pathways (Doerschuk 
et al., 2000). Neutrophil emigration become decisive on CD18-independent interactions 
in Streptococcus pneumonia, Staphylococcus aureus infection, hydrochloric acid, 
hyperoxia or complement-induced acute lung injury, where blockade of CD18-dependent 
components completely fails to alter neutrophil egress (Doerschuk et al., 1999). The 
molecular mechanisms of CD18-independent pathways have not been identified. 
Emerging evidence has highlighted importance of functional α4-integrins on neutrophil 
and α4-integrin/VCAM-1 interaction to temper inflammation (Ibbotson et al., 2001;Burns 
et al., 2001). 
Purinergic P2X7 receptor (P2X7R), an ATP-gated cation channel, is unique among all 
other family members because of its ability to respond to various stimuli and to modulate 
pro-inflammatory signaling. The activation of P2X7R has been shown to be an absolute 
requirement for mature IL-1β and IL-18 production and release from hematopoietic cells 
(Ferrari et al., 2006;Mehta et al., 2001). Loss of P2X7R exhibits resistance to collagen-
induced arthritis and fails to release IL-1β and IL-6 from peritoneal macrophages in 
response to systemic LPS and ATP challenge (Solle et al., 2001). P2X7R has been 
implicated in Alzheimer’s disease, rheumatoid arthritis, chronic lymphocytic leukemia 
and cancers (Li et al., 2006;Parvathenani et al., 2003;Mitsiades & Mitsiades, 2003). 
Recent findings have suggested the involvement of P2X7R in the pathogenesis of 
pulmonary emphysema, chronic obstructive pulmonary disease (COPD) and lung fibrosis 
(Muller et al., 2010;Cicko et al., 2010). We have previously shown that P2X7R from 
alveolar type I cells (AEC I) are functional and release ATP to regulate surfactant 
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secretion from AEC II in a paracrine fashion. P2X7R
-/-
 mice fails to reverse the surfactant 
increase following hyperventilation (Mishra et al., 2011a). However, functional studies 
exploring the role of P2X7R in acute lung injury in vivo are lacking. 
In the present study, we tested the hypothesis that P2X7R regulates neutrophil 
trafficking in the injured lung by stimulated ectodomain shedding of VCAM-1 from AEC 
I surface. Employing an experimental strategy of clinically relevant two-hit injury model 
of moderate tidal volume MV and low dose LPS we tested this idea using P2X7R-null 
mice and selective P2X7R inhibition. Furthermore, we determined the role of VCAM-1 
on neutrophil recruitment into the alveolar space by functional blockade of VCAM-1 
activity. Our findings identified a specific pathway of neutrophil recruitment in vivo 
through sVCAM-1 shed from AEC I, providing a novel function of AEC I. 
Pharmacological targeting of P2X7R or VCAM-1 may constitute a new strategy for the 
treatment of acute lung injury. 
3.3 Materials and Methods 
3.3.1 Mice  
All animal procedures were approved by the Institutional Animal Care Committee of 





breeder mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and bred 
in the Animal Resource Unit of Oklahoma State University. The animals between 6-8 
weeks old were used for experiments. 
3.3.2 Murine model of acute lung injury 
We used a modification of the murine two-hit lung injury model with a low dose LPS 
pretreatment, followed by mechanical ventilation (Altemeier et al., 2005). Mice were 
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randomly assigned one of four groups: 1) spontaneous breathing non ventilated control 
(CONT), 2) mechanical ventilation (MV), 3) LPS or 4) LPS with mechanical ventilation 
(LPS+MV). Mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) 
intraperitoneally. Tracheotomy was performed through the anterior neck soft tissues to 
expose the trachea. A 22-gauge needle was inserted into the trachea. Mice were placed in 
a supine position on a warming device with a heating lamp to maintain the body 
temperature to 37°C throughout the experiment. Mice were instilled with pyrogen-free 
saline (1.5 µl/g) or LPS (Escherichia coli serotype 0111:B4, Sigma-Aldrich; 0.5 µg/g 
bodyweight, 1.5 µl/g), through the inserted needle. Sixty minutes after instillation, mice 
were ventilated on a small animal ventilator (SAR-830/AP; CWE Inc) with following 
settings: respiratory rate = 125 breaths per minute; inspiratory and expiratory ratio = 1:2; 
tidal volume (Vt) = 12 ml/kg bodyweight; PEEP = 3 cm of H2O and an inspired oxygen 
fraction of 0.21 for 150 min. Mice were given xylazine and ketamine, both at half of the 
initial dosage intraperitoneally at every 1 hr interval throughout the experiment for 
adequate sedation. 
In separate experiments, LPS was co-administered into the lung with AZ10606120-
dihydrochloride (P2X7R antagonists, 100 µM, final volume 1.5 µl/g b.wt, Tocris Biosci, 
Ellisville, MO), functional blocking monoclonal antibody against VCAM-1 (88 
µg/mouse, purified rat anti-mouse CD-106, Pharmingen, San Diego, CA) and isotype–
matched control (purified rat IgG2a κ isotype control, Pharmingen) in wild-type mice or 
recombinant VCAM-1 (5 µg/mouse, recombinant mouse VCAM-1/CD106 Fc chimera, 
R&D Systems, Minneapolis, MN) in P2X7R
-/-
 mice. Mechanical ventilation with the 
same settings was started after 60 min and continued for additional 150 min as described 
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above. At the end of protocol, mice were euthanized and exasanguinated via abdominal 
aorta puncture. 
3.3.3 Bronchoalveolar lavage  
Bronchoalveolar lavage (BAL) was performed using 1 ml of 0.9% sterile saline for 3 
times. BAL recovered were pooled and centrifuged at 250 g for 10 min. The BAL fluid 
was used for total protein and cytokine analyses. The harvested lung tissue samples were 
snap-frozen and stored in liquid nitrogen in aliquots at – 80°C for biochemical and gene 
expression analyses. Cell pellets were cytospun at 600 g for 10 min. Total cell numbers 
were counted with a standard hemocytometer. Differential cell counting was done using a 
modified Wright Giemsa stain. A total of 500 cells were counted from randomly chosen 
fields from each sample. The total protein concentration in the BAL fluid was determined 
by the bicinchoninic acid method (BCA protein assay kit; Pierce, Rockford, IL) with 
bovine serum albumin as standards. 
3.3.4 Cytokine antibody array 
BAL fluids from wild-type and P2X7R
-/-
 mice were assayed for cytokines using the 
RayBio Mouse Cytokine Antibody Array (C-series 2000, RayBiotech, Inc., Norcross, 
GA), according to the manufacturers’ instruction. In brief, BAL fluids pooled from three 
mice in each group were added to pre-blocked protein array membranes overnight at 4ºC. 
Array membranes were washed three times with wash buffer and incubated with biotin-
conjugated anti-cytokine antibodies for 2 hours at room temperature. After washing, 
streptavidin-horseradish peroxidase were added and incubated for 2 hours. Protein array 
membranes were incubated 1 min for detection and then exposed to Kodak films. The 
resulting membrane films were quantified using Quantity One software Tool (Bio-Rad, 
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Hercules, CA). To eliminate the loading difference the average optical densities (OD) of 
each cytokine was normalized to the average OD of biotin-conjugated positive control 
samples (upper left and lower right of each membrane). Fold change was then determined 
as the difference between CONT and LPS+MV treated conditions. 
3.3.5 ELISA 
sVCAM-1, IL-1β, IL-6, TNF-α, MCP-1 and IgM concentrations in BAL and/or serum 
were determined by ELISA, according to the manufacturers’ recommendations (mouse 
IgM ELISA kit; Bethyl Labs, Inc., Quantikine mouse IL-1β and sVCAM-1 
immunoassay; R&D Systems, Minneapolis, MN; and mouse IL-6, TNF-α, and MCP-1 
ELISA Ready-SET-Go; eBiosciences, San Diego, CA). Undiluted samples were used to 
maximize detection level. The sensitivity were 1.37 ng/ml for IgM, 0.3 ng/ml for 
sVCAM-1, 4 pg/ml for IL-6 and 8 pg/ml for IL-1β, TNF-α, and MCP-1, respectively. 
A cell based ELISA assay were developed in isolated rat alveolar macrophages from 
BAL for the sVCAM-1 binding experiments. Alveolar macrophages were cultured in 96-
well micro titer plates (Costar, Cambridge, MA) in DMEM. Cells (0.2 X 10
6
/well) were 
plated for 1 hour and incubated with different concentrations of sVCAM-1 (0, 100, 1000, 
10000 ng/ml) in DMEM for 45 min at 37°C. After carefully washing with PBS, cells 
were incubated for 1 hour with rabbit anti-rat-VCAM-1 detector antibody (Abcam, 
Cambridge, MA) or a preimmune IgG fraction at a concentration of 50 µg/ml. This was 
followed by anti-rabbit horseradish peroxidase-conjugated antibody (1/5000 dilution, 
Amersham, Arlington Heights, IL) incubation for 45 min. The assay was developed by 
addition of o-phenylenediamine dihydrochloride substrate and the reaction was stopped 
by 50 µl of 3 M H2SO4. Optical density (OD) was measured at 490 nm.  
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3.3.6 Nitrite/nitrate production 
Rat alveolar macrophages were seeded at density of 1 X 10
6
/ml in 12-well culture 
plates (Falcon Laboratories) in DMEM supplemented with 10% FBS, penicillin and 
streptomycin (GIBCO). Cells were incubated for 1 hour, to remove unattached cells, and 
incubated with LPS (1 µg/ml) or VCAM-1 (10 µg/ml) for 4 hours. Nitrite and nitrate 
concentrations in cell-free culture supernatants were determined using NADPH-
dependent nitrate reductase assay (Green et al., 1982). Briefly, samples were reacted with 
1% sulfanilamide, 0.1 % naphthyl-ethelene diamine at room temperature for 10 min and 
the nitrite concentration was determined by absorbance at 540 nm with standard solutions 
of sodium nitrite run in parallel.  
3.3.7 Lung tissue myeloperoxidase 
Whole lung tissue was homogenized in 1 ml of 50 mM potassium phosphate, pH 6.0 
and centrifuged at 14,000 g for 15 min at 4°C. The pellet was redissolved in the 
phosphate buffer containing 50 mM hexadecyltrimethylammonium bromide. The 
samples were sonicated on ice for 20 seconds, freeze-thawed twice and centrifuged at 
14,000 g for 10 min at 4°C. One hundred µl of undiluted samples were added 
immediately to 2.9 ml of phosphate buffer containing 0.167 mg/ml O-danisidine 
dihydrochloride and 0.0005% hydrogen peroxide in cuvettes and absorbance at 460 nm 
was measured for 5 min. Myeloperoxidase (MPO) activities were expressed as 
absorbance per min per milligrams of total protein. 
3.3.8 Lung microvascular permeability 
Lung microvascular permeability in wild-type and P2X7R
-/- 
mice were assessed by a 
modified Evans blue (EB) dye extravasation method as previously described (Chen et al., 
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2006). Extravasations of EB dye into the extravascular pulmonary tissue spaces were 
used as a quantitative measure of changes in lung microvascular permeability. In brief, 
EB dye (20 mg/kg body weight) was injected into the jugular vein of the animals after 
LPS instillation and ventilated for 3 hour. The lungs were perfused with 1 ml of 0.9% 
sterile saline via right ventricle to remove the remaining blood from pulmonary 
circulation. Lungs were harvested and weighed. EB dye was extracted from lung 
homogenates following incubation with formamide 8 ml/gm wet tissue for 48 hours at 
room temperature and centrifuged at 2,000 g for 30 min. EB dye concentrations in the 
lung tissue were quantified by measuring absorbance at 620 nm from a standard curve. 
The total amount of EB dye present in the pulmonary tissues were quantified and 




 mouse lungs (n=6) were instilled with 4% paraformaldehyde 
in PBS at 20 cm H2O pressure and fixed for 48 hours, embedded in paraffin and 
sectioned at 4 µm thickness. The sections were stained with hematoxylin and eosin and 
were examined under a light microscope.  
3.3.10 Isolation and culture of mouse AEC II 
Murine alveolar epithelial type II cells (AEC II) were isolated from wild-type and 
P2X7R
-/-
 mice (6-8 weeks of age) as described previously (Corti et al., 1996). Lung was 
perfused free of blood with solution containing 0.9% NaCl, 0.1% glucose, 10 mM 
HEPES, pH 7.4, 5 mM KCl, 1.3 mM MgSO4, 1.7 mM CaCl2, 0.1 mg/ml streptomycin 
sulfate, 0.06 mg/ml penicillin G, 3 mM Na2HPO4 and 3 mM NaH2PO4. AEC II were 
released from the lung by enzymatic digestion with dispase (2500 caseinolytic units/ml, 
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BD Biosciences, Franklin Lakes, NJ) instilled (0.5 ml) via the trachea for 15 min. Three 
lungs were isolated, chopped and pooled into a beaker. The lung slices were further 
digested with DNase I (100 µg/ml) for 45 min at 37
o
C in a 50 ml beaker (~17 ml 
digestion cocktail) with intermittent shaking. The digested lungs were filtered through 
160-, 37- and 15-µm nylon mesh sequentially. The filtrate was centrifuged at 250 xg for 
10 min. The cell pellet was resuspended in DMEM media (GIBCO, Grand Island, NY) 
and incubated in a 100 mm petridish coated with mouse IgG (75 µg/dish) for 1 hour. 
The cells were spun down at 250 x g for 10 min and resuspended in DMEM containing 
10% FBS. The cell yield was ~10 x10
6
 per isolation and the cell viability was >97% by 
trypan blue exclusion. AEC II were then cultured in fibronectin coated 12-well tissue 
culture plates (corning) at 1x 10
6 
cells/well in DMEM supplemented with 10% FBS, 
penicillin and streptomycin (GIBCO). AEC II was cultured for three days to allow them 
trans-differentiate into AEC I. For dose–response experiments, day 3 cultured cells 
were stimulated with IL-1β (0, 0.1, 1, 10 or 100 ng/ml, R&D Systems, Minneapolis, 
MN) for 24 and 48 hours. In separate experiments, day 3 cultured AEC were stimulated 
with IL-1β (10 ng/ml) in the presence or absence of the MMP inhibitor, GM-60001 (50 
µM, EMD Millipore, Billerica, MA) for 48 hours. ADAM-17 (5 ng/ml) (R&D Systems, 
Minneapolis, MN) was added at the last 3 hours of incubation, media were collected for 
determining sVCAM-1 by ELISA. 
3.3.11 Isolation and culture of mouse AEC I and AEC II 
Murine AEC I and AEC II were freshly isolated from C57BL/6 mice (6-8 wks 
of age) following LPS+MV injury (Mishra et al., 2011b). Briefly, lungs were perfused 
with solution (containing 0.9% NaCl, 0.1% glucose, 10 mM HEPES, pH 7.4, 5 mM 
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KCl, 1.3 mM MgSO4, 1.7 mM CaCl2, 0.1 mg/ml streptomycin sulfate, 0.06 mg/ml 
penicillin G, 3 mM Na2HPO4 and 3 mM NaH2PO4) followed by instilling 1 ml of the 
digestion cocktail (dispase, 2500 caseinolytic units/ml and elastase, 4 U/ml in solution) 
directly through the trachea. Three lungs were isolated, pooled into a beaker containing 
~17 ml of the digestion cocktail and incubated at 37
o
C for 15 min. After incubation, the 
lungs were chopped. Lung tissues were further digested with the addition of DNase I 
(100 µg/ml) for 45 min at 37
o
C with intermittent shaking. The digested lungs were 
filtered through 160-, 37- and 15-µm nylon mesh sequentially. The filtrate was 
centrifuged at 250 xg for 10 min. The cell pellet was resuspended in DMEM media and 
incubated in a 100 mm petridish coated with mouse IgG (75 µg/dish) for 1 hour. The 
cells were spun down at 250 xg for 10 min and resuspended in DMEM containing 10% 
FBS. The cell yield was ~8 x10
6
 per mouse and the cell viability was >95%.  
3.3.12 Flow Cytometry 
The surface expression of integrins on neutrophils was determined using 
fluoroscein isothiocynate (FITC)-conjugated integrin α4, CD-11b and integrin β7 (rat 
IgG2b, κ; Pharmingen, San Diego, CA) and a phycoerythrin (PE)-conjugated mAb 
against the murine granulocyte marker Gr-1(RB6-8C5; Pharmingen) by fluorescence 
activated cell sorter (FACS). Blood neutrophils (10
6 
cells in 100 µl staining buffer, PBS 
containing 1% bovine serum albumin and 0.1% sodium azide) or BAL cells (1 X 10
5
 
cells in 100 µl staining buffer) were incubated for 45 min at 4ºC with FITC- and PE-
conjugated antibodies. Cells were also labeled with isotype control rat anti-mouse IgG 
antibodies. The cells were then washed twice with the staining buffer. 
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AEC I and AEC II were stained with PE-conjugated podoplanin (AEC I cell 
marker) (BioLegend, San Diego, CA) and FITC-conjugated monoclonal-VCAM-
1(Abcam, Cambridge, MA). Fluorescence was determined on a single argon laser 
cytofluorometer FACSCalibur (BD Biosciences) and analyzed using CELLQuest 
software. Granulocyte, lymphocyte and monocyte (or macrophage) populations were 
delineated using forward- and side- scattering properties of the three cell populations. 
Mean fluorescence intensity (MFI) values were determined from the histograms of the 
gated populations, and each mean fluorescence was obtained by subtracting the measured 
control IgG fluorescence from the mean fluorescence for the population. 
3.3.13 Chemotaxis assay 
Peripheral rat blood neutrophils were isolated using OptiPrep 
TM
 density gradient 
(Sigma, St. Louis, MO). Circulating neutrophils were isolated from EDTA-anti-
coagulated whole blood collected by abdominal aorta puncture. Briefly, red blood cells 
were removed by hypotonis lysis. Neutrophils were further purified by centrifugation 
through a Histopaque density gradient and resuspended in HBSS (2 X 10
7
/ml). 
Chemotaxis of neutrophils was conducted in duplicate using 3-µm 
polyvinylpyrrolidone-free polycarbonate membranes (Nuclepore Corp.,Pleasanton, CA) 
in Boyden-chambers . Mouse recombinant VCAM-1 (R&D Systems) was diluted in 
media and placed in the lower wells (200 µl) at a concentration of 10 µg/ml of the 
transwell. In some experiments BAL fluid or cultured AEC (50% conditioned media) 
from wild-type and P2X7
-/-
 mice were kept in lower chambers. Neutrophils were pre-
activated with dihydrochalasin B (a known inducer of surface integrin expressions, 2.5 
µM/ml) for 10 min. One hundred micro liters of neutrophils at 1X10
6
 cells/ml were 
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placed in the upper chambers. The loaded chambers were incubated at 37ºC in humidified 
air containing 5% CO2 for 1 hour. The membrane was then removed, fixed and stained 
with Wright Giemsa stain. The cells that migrated and adhered to the lower surface of the 
membrane were counted from 10 microscope fields under the x 10 objectives (Olympus). 
Data are expressed as average number of neutrophils per field. 
3.3.14 Western blot 
Lung homogenate and cell lysates were separated on a 10% SDS-polyacrylamide
 
gel 
and transferred to a nitrocellulose membrane. The membrane
 
was stained with Ponceau S 
to ensure proper transfer and blocked
 
overnight with 5% dry skim milk in 100 mM Tris-
buffered
 
saline plus 0.1% Tween 20 (TBST). The membranes were incubated
 
with anti-
pERK1/2, total ERK1/2 antibodies (Cell Signaling Technology, Danvers, MA) at a 
1:1000 dilution or anti-β actin at a 1:2000 dilution overnight at 4°C. After being
 
washed 
with TBST three times, the membranes were incubated with horseradish
 
peroxidase-
conjugated anti-rabbit IgG (1:2000)
 
for 1 hour. The blots were washed again and 
individual target
 
proteins were visualized using the enhanced chemiluminescence
 
detection system (Amersham Biosciences, Piscataway, NJ). 
3.3.15 Real-time PCR 
Quantitative real-time PCR was performed to measure the relative levels of cytokine 
and chemokine transcripts. Total RNA was extracted using the TRI Reagent (Molecular 
Research Center Inc., Cincinnati, OH) and reverse-transcribed into cDNA using Moloney 
murine leukemia virus reverse transcriptase (Invitrogen) and gene-specific primers (Table 
1). The quantitative real-time PCR was done using an ABI prism 7700 system (PE 
Applied Biosystems, Foster city, CA). The expression levels were normalized with 18S 
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3.3.16 ADAM-17 activity assay 
Freshly isolated AEC I and AEC II from wild-type and P2X7R
-/-
 with or without 
LPS+MV or HEK cells stably expressing rat-P2X7 receptor (HEK-P2X7R) treated with 
BzATP (200 µM, Sigma) or the ERK1/2 inhibitor (10 µM, Promega, Madison, WI) for 
indicated time periods were lysed. The lysate (25 µg) were analyzed for ADAM 17 
activity using a fluorogenic peptide based assay kit (R&D Systems, Minneapolis, MN) . 
The enzymatic activity was obtained from a serially diluted standard of recombinant 
ADAM17 run in parallel. 
3.3.17 Zymography 
Standard gelatin zymography was done to evaluate the activity of matrix 
metalloproteinase (MMP) 2 and 9 in BAL fluid from wild-type and P2X7R
-/-
 mice. Ten 
microgram proteins of BAL fluid were separated in an 8% SDS-polyacrylamide gel 
containing 0.2% gelatin. The gel was washed and stained with Commassie Blue and 
destained with a mixture of acetic acid and methanol. Gels were scanned and the band 
intensities were quantified (in arbitrary density units) using Image J software (National 
Institute of Health, USA). To eliminate the differences between gels, two samples of all 
experimental groups were loaded in the same gel. 
3.3.18 Statistical analysis 
The results were analyzed by one-way ANOVA with posthoc Tukey’s test for 
multiple comparisons of control and treatment groups. A two-tailed Wilcoxon ranked test 
was used for non-parametric data, using Graph pad Prism software (version 4). All results 
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were reported as means ± SE (n=4-8). Difference was considered statistically significant 





3.4.1 P2X7R-/- mice and P2X7R antagonism protects against acute lung injury  
MV potentiates lung inflammation in the presence of LPS and increased cytokine 
levels, neutrophil transmigration, alveolar–capillary damage and protein leakage 
(Altemeier et al., 2005). The two-hit LPS+MV injury model is reproducible and 
recapitulates the aspects of acute lung injury in humans (Kallet et al., 2005). We 
examined whether P2X7R
-/- 
mice or pharmacological inhibition of P2X7R in wild-type 
mice would provide protection against LPS+MV-induced lung injury. The total cell 
counts in the BAL from wild-type mice were increased in the LPS+MV group in 
comparison with the control group. Neutrophil was the major recruited cell type in our 
experimental model of acute lung injury as revealed by differential cell count analysis 
(7.06 ± 1.01 in LPS+MV vs. 0.04 ± 0.007 X 10
4
 neutrophils/ml in CONT, respectively). 
This recruitment of neutrophil was ~ 7-fold higher in wild-type compared to P2X7R
-/-
 
mice. Intratracheal administration of the P2X7R inhibitor, AZ 10606120 dihydrochloride 
showed significantly less neutrophil in BAL (Figure 3.1A). Lung MPO activity was 4-
fold increased by LPS+MV in wild-type mice. This increase was absent in P2X7R
-/-
 mice 
(Figure 3.1B).  
Lung vascular permeability was assessed using the Evans blue dye extravasations 
method (Chen et al., 2006). LPS+MV caused significant accumulation of dye in the lungs 
of wild-type, but not in P2X7R
-/-
 mice (Figure 3.1C). However, there was no significant 
difference in dye accumulation between wild-type and P2X7R
-/-
 mice without LPS+MV 
treatment. Importantly, BAL IgM concentration was ~ 5 fold increased by LPS+MV in 
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wild-type, which was significantly attenuated in P2X7R
-/-
 mice and following P2X7R 
inhibition (Figure 3.1D).  
BAL IL-1β, IL-6, and MCP-1 levels were increased following LPS+MV in wild-
type (Figure 3.1E-G). LPS+MV-induced increases in IL-1β, IL-6, and MCP-1 in BAL 
were less after pharmacological inhibition of P2X7R and in P2X7R
-/- 
mice. mRNA levels 
of IL-1β, IL-6 and MCP-1 were also increased by LPS+MV (Figure 3.2A-D). The 
mRNA induction of these cytokines was 30-50% less in P2X7R
-/-
 mice in comparison 
with that in wild-type mice. The result indicates that P2X7R also regulates cytokine 
expression. However, TNF-α expression from wild-type and P2X7R
-/- 
mice lung tissues 
had little differences (Figure 3.1H). Taken together, these results demonstrate that P2X7R
 
contributes to alveolar-endothelial infringement and cytokine induction and release 




Histological examination of lung tissue from wild-type mice with LPS and MV 
showed evidence of diffuse lung injury with significant inflammatory cell infiltrate 
around the interstitial, peri-vascular and intra-alveolar spaces (Figure 3.1I). There were 
widespread infiltration of neutrophil within alveolar septa and lumens. In sharp contrast 
to the wild-type mice, the P2X7R
-/-
 mice instilled with LPS and MV exhibited less 
evidence of neutrophil infiltration. For example, the multiple foci of neutrophil 
infiltration occurred in the wild-type mouse lung, which were not detected in the P2X7R
-/-
 
mice. Similarly, numerous scattered foci of alveolar septal necrosis seen in wild-type 


















Figure 3.1: Reduced inflammation during acute lung injury in P2X7R
-/-
 or P2X7R 
antagonism. 
(A) Neutrophil in the BAL of wild-type and P2X7R
-/-
 mice or following P2X7R inhibition 
from LPS+MV as described in Materials and Methods. Data are expressed as mean ± SE 
(n=6-8). (B) MPO activity (C) Evans blue dye extravasations in wild-type and P2X7R
-/-
 
mice were quantified. Evans blue dye (20 mg/kg bodyweight) is injected intravenously to 
LPS+MV treated mice and extracted from lungs. Data are expressed as mean ± SE (n=4-
8 animals). (D) IgM, (E) IL-1β and (F) IL-6 (G) MCP-1 and (H) TNF-α concentrations in 
BAL of control and LPS+MV in the presence or absence of P2X7R antagonist from wild-
type and P2X7R
-/-
 mice. Data are expressed as mean ± SE (n= 4-6). (I) Histological 
analysis of inflamed lungs of wild-type and P2X7R
-/-
 mice. Parrafin sections (4 µm) of 
lungs were stained with H&E from (a) wild-type and (b) P2X7R
-/-
 control compared to 
LPS+MV (c and d, respectively). Red arrow indicates alveolar septal necrosis (Scale bar= 






Figure 3.2:  Pro-inflammatory cytokine expression in P2X7R-/- mice lung  
(A) IL-1β, (B) IL-6, (C) MCP-1 and (D) TNF-α expressions were measured in lung 
homogenates from control (CONT) or LPS combined with mechanical ventilation 
(LPS+MV) mice. Data are expressed as means ± SE (n=3-4 animals/group) and 
compared with corresponding wild-type and P2X7R
-/-











Gene  Forward primer sequences Reverse primer sequences 
mIL-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
mIL-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
mTNF-α CCGGGAGAAGAGGGATAGCTT TCGGACAGTCACTCACCAAGT 
 mMCP-1 CTTCTGGGCCTGCTGTTCA CCAGCCTACTCATTGGGATCA 
rat IL-1β TTGCTTCCAAGCCCTTGACT TGAGTGACACTGCCTTCCTGAA 
rat IL-6 CCACCAGGAACGAAAGTCAAC TGTCAACAACATCAGTCCCAAGA 
 18 S ATTGCTCAATCTCGGGTGGCTG CGTTCTTAGTTGGTGGAGCGATTTG  
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3.4.2 P2X7R regulates soluble VCAM-1 (sVCAM-1) release in acute lung injury  
P2X7R has previously been shown to be a prime regulator of mature IL-1β 
processing and release in vitro (Ferrari et al., 2006;Mehta et al., 2001) and in vivo (Solle 
et al., 2001). To further elucidate the P2X7R-mediated mechanisms of lung inflammatory 
response, we screened 144 cytokines in BAL from wild-type and P2X7R
-/-
 mice using 
cytokine array (Figure 3.3A). The array detects- acute phase cytokines, chemokines, and 
soluble mediators in biological fluids. 54 cytokines were detectable following LPS+MV. 
There was significant induction of 34 cytokines in both genotypes following lung injury. 
Among them 25 cytokines shows no difference in induction level between wild-type and 
P2X7R
-/-
 mice (Table 3.2). The cytokine array confirms the ELISA results which shows 
inadequate IL-6, MCP-1, and unaltered levels of TNF-α between wild-type and P2X7R
-/-
 
mice in response to injury (Figure 3.1F-H). IL-1β was not detected due to the low 
expression level. Notably, soluble VCAM-1 and P-Selectin were induced by LPS+MV in 
wild-type, but not in P2X7R
-/-
 mice (Figure 3.3B). 
To verify our array results, we next determine the levels of soluble VCAM-1 and 
P-Selectin in BAL. LPS+MV significantly induces sVCAM-1 release in wild-type mice. 
There was significant decrease in sVCAM-1 level in BAL following P2X7R antagonism 
or from P2X7R
-/-
 mice. (Figure 3.3C). However, there was no change observed in soluble 









Figure 3.3: sVCAM-1 release is compromised in P2X7R
-/-
 mice following acute lung 
injury:  
(A) A presentative protein-array membrane obtained from incubation with BAL fluid 
from control or LPS combined with mechanical ventilation (LPS+MV) as indicated. 
Positive controls are circled in red and were used for data normalisation. P2X7R
-/-
 mice 
shows altered IL-6 (purple), IL-12 (yellow), MCP-1 (green), and sVCAM-1 (blue) 
release following LPS+MV. (B) Comparison of changes in soluble mediator release 
induced by LPS+MV plotted as fold increase over respective control from BAL of wild-
type and P2X7R
-/-
. (C) sVCAM-1 and (D) s-P-Selectin levels in the BAL of wild-type and 
P2X7R
-/-
 mice and following P2X7R inhibition after lung injury. sVCAM-1 and sP-
Selectin were quantified by ELISA. Each data point from individual animals are 











3.4.3 Soluble VCAM-1 activates alveolar macrophages and potentiates neutrophil 
chemotaxis 
To obtain information related to soluble VCAM-1 function in the lung, we first 
examined the binding of sVCAM-1 to rat alveolar macrophages by means of a cell-based 
ELISA. The cells were incubated with different concentrations of sVCAM-1 (0-10,000 
ng/ml), and then anti-VCAM-1or preimmune IgG was added. The OD was directly 
proportional to the sVCAM-1 concentrations added to the wells, indicating binding and 
immobilization of the antibody to VCAM-1 present on the surfaces of alveolar 
macrophages (Figure 3.4A). No increase was observed in binding of preimmune IgG to 
cells, indicating the Fc receptor-independent binding of the antibody in alveolar 
macrophages. Furthermore, the binding of sVCAM-1 to alveolar macrophages increases 
nitrate/nitrite production (Figure 3.4B). In addition, VCAM-1 stimulation induces  
expressions of IL-1β and IL-6 mRNA (Figure 3.4C-D), indicating binding of sVCAM-1 
to alveolar macrophages is able to activate and intensify inflammatory response through 
enhanced cytokine induction.   
VCAM-1 in solution acts as a soluble agonist and adhere with higher avidity to 
α4β1 integrin expressing cells (Woodside et al., 2006) and promotes cell migration and 
aggregation (Nakao et al., 2003b). Our results show increases in BAL sVCAM-1 
concentrations and neutrophilia in wild-type mice, but not in P2X7R
-/- 
mice following 
LPS+MV. To examine whether sVCAM-1 is a chemoattractant for neutrophils, a series 
of chemotaxis assay were performed. Peripheral rat neutrophils responded avidly to the 
known chemotactic stimulus fMLP (100 µM), (187.4±19.17 neutrophil/field). Neutrophil 
migration was also markedly increased by recombinant VCAM-1 (97±5.3 vs. 24±2.1 
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neutrophil/field) (Figure 3.4E). Next, the BAL samples from LPS+MV–treated wild-type 
and P2X7R
-/-
 mice were neutralized with blocking monoclonal antibody against VCAM-
1. Neutrophil chemotaxis was significantly compromised in presence of VCAM-1 
neutralization compared to the respective isotype control (160.4±8.9 in control 
vs.51.3±6.4 in anti-VCAM-1), indicating BAL VCAM-1 is the key mediator of increased 
neutrophil flux in acute lung injury. In presence of BAL from P2X7R
-/- 
mice, neutrophil 
migration was relatively less responsive (100.5±8.8 neutrophil/field). This implies 









Figure 3.4: VCAM-1 activates macrophages and induces neutrophil chemotaxis.  
(A) The binding of sVCAM-1 to alveolar macrophages. As described in Materials and 
Methods a cell-based ELISA has been developed using rat alveolar macrophages. 
Binding of sVCAM-1 with different concentrations were monitored following incubation 
with the detector anti-VCAM-antibody. Increase in OD was proportional to the sVCAM-
1 concentrations. VCAM-1 activates alveolar macrophages and increases (B) 
nitrate/nitrite production (C) IL-1β and (D) IL-6 mRNA. (E) Chemotaxis assays on rat 
peripheral neutrophil. Briefly, neutrophils were pre-treated with dihydrochalasin B (2.5 
µM) for 10 minutes and then placed on the upper chamber. Murine sVCAM-1 (10 µg/ml) 
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and fMLP (100 µM, a positive control), and control media was added in the bottom 
wells. LPS+MV treated-BAL from wild-type mice or P2X7R
-/-
 mice were incubated for 
30 minutes with anti-VCAM-1 antibody or isotype control IgG (20 µg/ml) and placed at 
the lower chamber. The membrane was then removed, fixed and stained with Wright 
Giemsa stain. The cells that migrated and adhered to the lower surface of the membrane 
were counted from 10 microscopic fields under 40X objective. The data are expressed as 




3.4.4 Anti-VCAM-1 antibody blocks LPS+MV-induced BAL neutrophilia and 
reverts lung injury in P2X7R-/- mice with recombinant-VCAM-1 
To determine whether sVCAM-1 is responsible for neutrophil recruitment in vivo 
we neutralized VCAM-1 in alveoli with anti-VCAM-1 antibody. Intratracheal blockade 
of VCAM-1 yielded a striking decrease in lung neutrophil sequestration in wild-type 
compared to the corresponding isotype controls (6.5 ± 0.14 vs.0.87 ± 0.2 X 10
4
/ml 
neutrophil) (Figure 3.5A). However, there was no significant difference observed in 
macrophage recruitment following treatment (Figure 3.5 B), indicating that neutrophils 
are the potent responders to VCAM-1 in the acute phase of inflammation. The release of 
IL-1β, IL-6, and MCP-1 (Figure 3.5C-E) into alveolar space was significantly reduced by 
VCAM-1 blockade.  
Next, to demonstrate directly the less neutrophil infiltration phenotype in P2X7R
-/-
 





 which develops less leukosequesterd-phenotype in response to 
LPS+MV shifted towards an amplified neutrophil recruitment in presence of recombinant 
VCAM-1 (4.8 ± 0.6 X 10
4
/ml). Instillation of recombinant-VCAM-1 to the lung of 
P2X7R
-/-
 mice restored lung neutrophil infiltration following LPS+MV challenge 
(compare Figure 3.1A and 3.5A). BAL IL-1β, IL-6 and MCP-1 levels in BAL were also 
increased by VCAM-1 reconstitution. Our results suggest that the amplified neutrophil 
recruitment in the wild-type mice following LPS+MV is a consequence of increased 
VCAM-1 shedding in BAL and is P2X7R-dependent. Together, these data demonstrate a 









Figure 3.5: VCAM-1 neutralization in wild-type mice protects acute lung injury and 
is revert in P2X7R-/- mice in presence of recombinant VCAM-1 reconstitution.  
Effect of function-blocking monoclonal antibody (mAb) against VCAM-1 in wild-type or 
reconstitution of recombinant-VCAM-1 in P2X7R
-/-
 mice on alveolar accumulation of (A) 
Neutrophil (B) Macrophage (C) IL-1β, (D) IL-6 and (E) MCP-1 following LPS+MV. 
Wild-type mice were intratracheally co-administered with isotype-matched control IgG 
or function-blocking mAb against VCAM-1 (88 µg/mouse) and P2X7R
-/-
 mice with 
murine recombinant VCAM-1 (5 µg/mouse) instilled along with LPS and ventilated as 
indicated in Materials and Methods. IL-1β, IL-6 and MCP-1 concentrations were 





3.4.5 Systemic response to acute lung injury in P2X7R
-/-
 mice   
Surface expression of β1 and β2-integrins on neutrophil is low in normal 
physiological conditions and is modulated in acute lung injury (Ridger et al., 2001). We 
reasoned the sVCAM-1 mediated neutrophil sequestration in alveolar space requires up-
regulation of integrins responsible for VCAM-1 binding. To determine whether the 
expression of α4β1 (VLA-4, CD49d/CD29), α4β7 (LPAM-1, CD49d/CD103) and αMβ2 
(CD11b/CD18) is modulated during lung injury, we performed flow cytometric analyses 
of these integrins on the neutrophils obtained from either peripheral blood or BAL from 
wild-type and P2X7R
-/-
 mice following LPS+MV. LPS+MV up-regulated α4 level but 
had a modest effect on β7 and αM integrin levels on circulating blood neutrophils from 
wild-type mice (Figure 3.6A-C). In contrast, LPS+MV increased the levels of all three 
α4, β7 and αM integrins. Isotype (rat IgG2b, κ) control antibody yielded minimal 
fluorescence intensity on BAL neutrophils as compared to anti-α4, anti-αM and anti-β7 
antibody (Data not shown). There was no significant difference in the expression of α4, 
β7 and αM integrins on circulating and migrated neutrophils between wild-type and 
P2X7R
-/-
 mice. Cell surface expression of α4, β7 and αM integrin was similar between the 
two genotypes in untreated control group.  
We reasoned that the pulmonary origin of acute inflammation might propagate the 
effect systematically and could furthermore influence the neutrophil infiltrations to the 
lung. Serum sVCAM-1, IL-1β and IL-6 levels between wild-type and P2X7R
-/-
 mice 
following injury was compared. Serum sVCAM-1 concentrations were increased in wild-
type mice following LPS+MV. This increase in P2X7R
-/-
 mice was modest (Figure 3.6D). 





mice. There was marked increased in serum IL-1β and IL-6 levels in wild-type 
mice which is less in P2X7R
-/-
 mice (Figure 3.6E-F). Collectively, these results suggest 
that β7 and αM integrins on neutrophils play crucial role for the migration of neutrophil to 
alveolar space. Furthermore, the reduced neutrophil influx in P2X7R
-/-
 mice lung is due to 






Figure3.6: The systemic effect of LPS+MV in P2X7R-/- mice  
(A) α4 (B) β7 and (C) αM –integrin expression in circulating or infiltrated BAL neutrophil 
from wild-type and P2X7R
-/-
 mice following LPS+MV. For flow cytometric analyses, 
EDTA-blood was taken from inferior venacava, and red blood cells were hypotonically 
lysed. Neutrophils were separated and stained as described in Materials and Methods. 
Neutrophils were gated on a two-dimensional forward and side scattergram of the single 
argon laser cytofluorometer FACSCalibur (BD Biosciences). Gr-1 positive cells had 
forward and side scatter characteristics consistent with granulocytes. The fluorescence 
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intensity was measured for each sample from 5,000 Gr-1 bright cells. The mean 
fluorescence intensities (MFI) obtained when neutrophils from either wild-type and 
P2X7R
-/-
 mice were labeled with the isotype (rat IgG 2b, κ) control antibody and was 
subtracted from the α4, β7 and αM fluorescences.  (D) sVCAM-1 (E) IL-1β and (F) IL-6 
in serum from LPS+MV or control wild-type and P2X7R
-/- 
mice as determined by ELISA. 




3.4.6 P2X7R in AEC I is functionally active for VCAM-1 shedding and neutrophil 
chemotaxis 
The marked increase of sVCAM-1 in alveolar space suggests that alveolar 
epithelial cells are likely involved in VCAM-1 shedding in acute lung injury. We 
hypothesized that the reduced neutrophil flux seen in P2X7R
-/-
 mice were because of lack 
of P2X7R in AEC I due in part to less soluble VCAM-1 shedding. To test this, we 
assessed the trans-differentiated alveolar epithelial cells (AEC I-like cells) to shed soluble 
VCAM-1in the presence of pro-inflammatory IL-1β. VCAM-1 protein expression was 
increased during the trans-differentiation of AEC II to AEC I in culture (Figure 3.7A). 
Moreover, VCAM-1 was induced by IL-1β in wild-type AEC I, but not in P2X7R
-/-
 as 
determined by ELISA (Figure 3.7B). An elevated level of sVCAM-1 in the medium of 
the IL-1β–treated AEC I was observed. The IL-1β stimulated shedding of VCAM-1 was 
time-dependent. This stimulation was absent in AEC I from P2X7R
-/-
 mice (Figure 3.7C). 
Basal VCAM-1 shedding was comparable between wild-type and P2X7R
-/-
 from day 3 
and day 5 AEC I (Figure 3.7D). A marked increase in soluble form of VCAM-1 was 
observed with IL-β stimulation at doses of 1 ng/ml and above which was completely 
absent in AEC I from P2X7R
-/-
. IL-1β-stimulated shedding was blocked by the broad 
spectrum metalloprotease inhibitor, GM-6001 (Figure 3.7E).  
We sought to determine next the potency of shed sVCAM-1 from AEC I surface 
directly to neutrophil chemotaxis. Conditioned-media from IL-1β treated AEC I 
transferred to the lower-Boyden chamber amplifies the migration of neutrophil 
significantly in wild-type, but not from P2X7R
-/-
 (96.4±5.6 vs. 34.4±2.1) (Figure 3.7F), 
suggesting sVCAM-1 from AEC I is an efficient neutrophil chemoattractant and 
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differentially regulated in P2X7R
-/- 
mice. These data further indicate that AEC I is 
functionally active in VCAM-1shedding and P2X7R present in AEC I regulates the 







Figure 3.7: IL-1β induced VCAM-1 shedding from AEC I is P2X7R-dependent.  
(A) Western blot analysis of VCAM-1 in AEC II (D0) and trans-differentiated AEC I 
(D1-D4) (B) Expression of VCAM-1 in trans-differentiated AEC I from wild-type and 
P2X7R
-/-
 mice as measured by ELISA. Cells were allowed to adhere for 48 h followed by 
gentle washing with replacement of media for 3 days. AEC culture was stimulated with 
vehicle (Me2SO) or IL-1β (10 ng/ml). (C) Time-dependent increase in sVCAM-1 
shedding from wild-type AEC I by IL-1β stimulation on day3 and (D) Dose-response of 
sVCAM-1 shedding in IL-1β stimulated and (E) GM-6001-treated AEC I culture. 
Supernatants were collected following stimulations with different dosage (0.1-100 ng/ml) 
of IL-1β and GM-6001 for 48 hours. Supernatants are subjected to centrifugation before 
measurement by ELISA. There were increased levels of sVCAM-1 in the culture 
supernatant as a result of IL-1β stimulation at higher doses after 48 hour in wild-type, but 
not in P2X7R
-/-
. Data are expressed as means ± SE from 3 independent preparations, *p < 
0.05 vs. D5 wild-type control. (F) Migration of neutrophils towards conditioned-media 
collected from ± IL-1β-treated AEC I (10 ng/ml, 50% conditioned media were transferred 
to the lower chamber) from wild-type and P2X7
-/-
 mice and expressed as means ± SE 




3.4.7 Soluble VCAM-1 shedding from AEC I surface is a P2X7R-dependent ADAM-
17 mediated phenomenon 
To further characterize the mechanisms of induced VCAM-1 shedding from the 
AEC I, we adopted an ex vivo approach to measure ADAM-17 activity using freshly 
isolated AEC from wild-type and P2X7R
-/-
 mice following acute lung injury (Mishra et 
al., 2011b). Surface expression of VCAM-1 in AEC I was significantly induced by 
LPS+MV in wild-type, and was modest in P2X7R
-/-
 mice as determined by flow 
cytometry (Figure 3.8A). ADAM-17 activity in AEC from wild-type was increased by 
LPS+MV and this increase was less in AEC I from P2X7R
-/-
 mice (321.8±53.4 vs. 
193.4±19.6 ng/ml) (Figure 3.8B). In addition, the activation of P2X7R with BzATP 
increased ADAM-17 activity in a time dependent manner in HEK-P2X7R cells (HEK 
cells stably expressing rat-P2X7R) (Figure 3.8C). The BzATP stimulated increase in 
ADAM17 activity was significantly blocked in presence of the ERK1/2 inhibitor (Figure 
3.8D).Delving into the signaling pathway of P2X7R activation, we also examined the 
MAPK signaling pathway in AEC I-like E10 cells. BzATP stimulation increases 
phosphorylated pERK1/2 (Figure 3.8E), suggesting activation of P2X7R and engagement 
of MAPK signaling pathway in AEC I.  
To examine the effect of other proteases in the process of VCAM-1 shedding 
from AEC I, we tested the MMP activities in BAL. Moreover, MMP2 and MMP9 
activity in BAL from wild-type and P2X7R
-/- 
mice were similar following LPS+MV 
(Figure 3.8F-G), suggesting the stimulated shedding of VCAM-1 from AEC I is a 
P2X7R-dependent phenomenon coupling ADAM-17. Collectively, these results supports 
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that VCAM-1 shedding from AEC I surface is mediated by P2X7R stimulation and 




Figure 3.8: Shedding of VCAM-1 from AEC I is ADAM-17 mediated P2X7R-
dependent phenomenon.  
(A) FACS analysis of cell surface VCAM-1 expression in podoplanin (AEC I marker)-
positive cells and (B) ADAM-17 activity in freshly isolated alveolar epithelial cells 
(AEC) following LPS+MV from wild-type and P2X7R
-/-
 mice as described in Materials 
and Methods (n=3). (C) ADAM-17 activity in HEK-P2X7R cells following BzATP 
stimulation with different time periods and (D) in presence of ERK1/2 inhibitor. (E) 
Time-dependent increase in phosphorylated ERK1/2 following BzATP stimulation in 
AEC-I like cells (E10). (F-G) Zelatin zymography of MMP 2 and MMP 9 activity in 
BAL from wild-type and P2X7R
-/-
 ensuing LPS and MV. MMP 9 and MMP2 activity 








The classic paradigm of inflammatory signaling in the lung has focused on 
neutrophil recruitment and activation of leukocytes, with concomitant release of soluble 
mediators that amplify and accelerate the process. Migration of neutrophil into the lungs 
is central to the pathogenesis of acute lung injury and requires an integrative signal. Our 
study describes a mechanism in which three epithelial components – a plasma membrane 
bound receptor (P2X7R), a soluble adhesion molecule (sVCAM-1) and a 
metalloproteinase (ADAM-17) - act coordinately to direct neutrophils to injury sites. We 
identified P2X7R, the predominant pro-inflammatory receptor on alveolar epithelia, as a 
regulator for soluble VCAM-1 shedding in vivo and in vitro through ADAM-17-
dependent cleavage. Our data indicate that IL-1β rapidly induces VCAM-1 expression 
and cleaves the adhesion molecule from alveolar epithelial surface by activating ADAM-
17 protease in a P2X7R–dependent manner. The shed soluble VCAM-1 is then 
transported, either actively or passively, to the interstitial space creating a chemotactic 
gradient guiding neutrophils into the airspace. We propose that in response to injury, 
AEC I synthesize and shed VCAM-1 into the alveolar lining fluid. The P2X7R is a bona 
fide pro-inflammatory purinergic receptor and plays a crucial role in lung injury (Figure 
3.1).  
We used the two-hit moderate tidal volume MV and low dose LPS (LPS+MV)-
induced lung injury model, because it recapitulates the aspects of acute lung injury in 
humans (Spragg et al., 2010;Rubenfeld et al., 2005). The model is reproducible and 
reliable and generates an early inflammatory response in the lung with neutrophil influx, 
proinflammatory cytokine release and alveolar-capillary damage (Altemeier et al., 
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2004;Lopez-Aguilar et al., 2010). Priming of lungs with LPS makes the lungs more 
susceptible to mechanical ventilation (Wosten-van Asperen et al., 2010;Bregeon et al., 
2005). MV also potentiates lung inflammation and multi-organ dysfunction in the 
presence of whole bacteria like staphylococcus aureus and Escherichia coli (Dhanireddy 
et al., 2006). In the current study, the potential involvement of P2X7R in the early 
inflammatory response was evaluated in using the two-hit model (Figure 3.1). Acute lung 
injury was more severe in wild-type mice than that in the mice treated with P2X7R 
antagonist or P2X7R-deficient mice as evidenced by: (1) a greater accumulation of 
neutrophils in airway, alveolar and interstitial compartments, (2) an increased vascular 
permeability accompanied by increased exudation of plasma proteins, and (3) copious 
release of acute inflammatory cytokines and shedding of adhesion molecules in 
bronchoalveolar space (Figure 3.1 and 3.2).  
The alveolar epithelium has the capacity not only to respond to microbial products 
but also to integrate the pro-inflammatory cascades in triggering or worsening acute lung 
injury. A number of regulatory molecules for examples IL-1β, IL-6, MCP-1, KC have 
been suggested as putative candidates to amplify these inflammatory events in the lung 
(Skerrett et al., 2004b). The reduced levels of sVCAM-1 and concomitant less 
accumulation of neutrophil by LPS and MV in the lungs of P2X7R
-/-
 mice and following 
P2X7R antagonism provided an important clue to uncover the mechanism by which 
alveolar epithelium regulates neutrophil movement (Figure 3.2B). VCAM-1 is rapidly 
induced in epithelial cells in response to acute lung injury (Atsuta et al., 1997). Shedding 
of VCAM-1 is a common phenomenon of inflamed epithelia (Vanderstocken et al., 
2010). Interestingly, intelligible shedding mechanisms of these adhesion molecules were 
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attributed to its location on endothelial cells from the opposite sides of the alveolar wall 
(Mendez et al., 2008). VCAM-1 ectodomain shedding from the activated endothelial 
cells are the major source of the circulating VCAM-1. Cell and tissue specific disintegrin 
and metalloproteases family members have been shown to induce the release of the 
soluble form of VCAM-1 (Singh et al., 2005;Rizzoni et al., 2003). The current data 
suggests alveolar lining epithelium as a major source of soluble VCAM-1. Although 
cytokines are perceived to stimulate the induction of VCAM-1 on endothelial cells 
(Gerritsen & Bloor, 1993;Mchale et al., 1999), the present investigation is the first to 
definitively attribute VCAM-1 shedding from alveolar epithelial cells. Furthermore, the 
less VCAM-1 shedding and ADAM-17 activity in P2X7R
-/-
 mice following acute lung 
injury, along with our in vitro studies showing that IL-1β-induced VCAM-1 ectodomain 
shedding from cultured alveolar epithelial cells, indicates that P2X7R is a physiologic 
component of the shedding process of this adhesion molecule.  
The early emigration of circulating neutrophils into the airspaces results from 
interference with adhesion process of endothelial and epithelial membrane. The fact that 
neutrophils are normally in prolonged contact with capillary endothelium in the 
pulmonary vessels suggests that the mechanisms mediating migration of neutrophil into 
pulmonary capillary walls are different from other tissues (Downey et al., 1993;Erzurum 
et al., 1992;McDonald et al., 2010). This “sieving” process causes a large population of 
neutrophils to form a marginated pool within the lung. Indeed the lower transmural 
pressure and close proximity of pulmonary circulation, gradient of soluble mediators in 
the alveolar and interstitial space plays a major role in the inflamed lung. This scheme of 
neutrophil infiltrations into the lung following acute lung injury is mediated by CD18-
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dependent and –independent mechanism. Furthermore, in various models of lung injury, 
neutrophil influx is significantly reduced in mice treated with anti-ICAM-1, anti-CD18 or 
anti-CD11b antibodies (Kumasaka et al., 1996b;Folkesson & Matthay, 1997;Gao et al., 
2005). Though CD11b/CD18 integrins are found to be up-regulated in neutrophils, 
blockade with saturating CD18 and ICAM-1 monoclonal antibodies could only block 
40% of neutrophil influx to the lung (Gao et al., 2001). Despite the recognized 
importance of CD11b/CD18 integrins and ICAM-1-mediated pathways in early migration 
of neutrophils, surrogate sequestration mechanisms are operational in the lung (Burns et 
al., 2001;Doerschuk et al., 2000). As there was no difference in neutrophil surface 
integrin expression between wild-type and P2X7R
-/-
 mice, the major contribution of 
P2X7R to acute neutrophil sequestration likely lies in the dissipation of soluble VCAM-1 
rather than integrin expression (Figure 3.6). Given the high abundance of soluble VCAM-
1 on the surface of alveolar epithelial cells, one can envision alveolar epithelium is not 
only a responder to microenvironments, but also incept the inflammatory cell 
sequestrations in lung injury.  
The current immunoablation studies demonstrate that P2X7R on AEC I, critically 
regulates neutrophil influx into injured lung tissue. Complementary to our findings, 
targeting VCAM-1 associated pathways in disease models significantly reduces tissue 
damage, presumably due to reduced neutrophil influx (Tabary et al., 2006;Ibbotson et al., 
2001). Furthermore, in various models of injury, infection, and inflammation the influx of 
leukocytes are significantly impaired in mice deficient for the VCAM-1 (Cybulsky et al., 
2001) or in mice treated with anti-VCAM-1 antibodies (Bowden et al., 2002;Miyao et al., 
2006). In previous studies, α4/CD18-independent neutrophil influx has been reported to 
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play an important role during bacterial pneumonia (Kumasaka et al., 1996a;Tasaka et al., 
2002). Association of α4-integrin on activated neutrophils with VCAM-1 substrate 
increases rolling and adherence, independent of selectins and β2-integrins (Ibbotson et 
al., 2001;Reinhardt et al., 1997;Reinhardt & Kubes, 1997). The shear forces in 
pulmonary capillaries are less and sufficient to support the α4β1-integrin mediated 
tethering and adhesion interactions (Reinhardt et al., 1997). Nevertheless, the α4-
integrin/VCAM-1-pathway is rapidly induced irrespective of bone marrow response and 
is transferrable on neutrophils (Ibbotson et al., 2001). Functional blocking of VCAM-1 
activity is protective in our model of acute lung injury as evidenced by reduced 
neutrophil sequestration, and IL-1β and IL-6 production in BAL (Figure 3.5). This was 
due to the fact of VCAM-1 binding to alveolar macrophages intensifies the already 
activated inflammatory response. Moreover, in vitro migration of neutrophils toward 
neutralized BAL with anti-VCAM-1 antibody or from P2X7R
-/-
 mice was reduced 
significantly (Figure 3.4). The present demonstration of a clear predisposition to 
enhanced BAL neutrophil sequestration and BAL cytokinemia in P2X7R
-/-
 mice 
following recombinant VCAM-1 reconstitution may also lie in its rescued-phenotype to 
shed sVCAM-1 (Figure 3.5). In the P2X7R
-/-
 mice, reconstitution of VCAM-1 accelerated 
the neutrophil sequestration to levels equal to those in wild-type mice. In addition, 
conditioned media from stimulated alveolar epithelial cells strikingly increased the 
number of chemotaxed neutrophils and was significantly reduced in P2X7R
-/-
 (Figure 6). 
This suggests that the depleted neutrophil sequestration in P2X7R
-/-
 was linked to the 
reduced VCAM-1 shedding from alveolar epithelium. Thus, P2X7R is likely to accelerate 
leukosequestration via VCAM-1 shedding. Together with our data, these findings 
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indicate that sVCAM-1 is critical for directing the movement of neutrophils in inflamed 
lung tissues. This finding is particularly important given that soluble VCAM-1 is a 
critical chemoattractant for neutrophil and in light of the previous finding that α4-
integrin/VCAM-1 pathway conceivably induces inappropriate neutrophil sequestration 
(Ibbotson et al., 2001). 
Albeit the in vivo significance of VCAM-1 cleavage and shedding is incompletely 
understood, the observation of high levels of soluble VCAM-1 in BAL suggests a likely 
pathophysiological role in lung injury (Levesque et al., 2000). Recent studies report that 
VCAM-1 shedding can be mediated by two distinct metalloproteinase activities, a PMA 
inducible protease like TNF-α-converting enzyme (ADAM-17, TACE) and a constitutive 
VCAM-1 sheddase that is active under normal cell culture conditions (Garton et al., 
2003). In addition several juxtamembrane sheddase like neutrophil elastase, cathepsin G 
and proteinases have also been implicated in the generation of soluble VCAM-1 
(Levesque et al., 2001). However, a definitive role of these proteases for the generation 
of soluble VCAM-1 in vivo is not clear. In this study we show for the first time that 
VCAM-1 shedding is functional in AEC I and is increased in acute lung injury via P2X7R 
mediated activation of ADAM-17. Several lines of evidence support the model that the 
activation of P2X7R couples ADAM-17 induced soluble VCAM-1 generation from AEC 
I. First, VCAM-1 expression is specifically induced in trans-differentiated AEC II by IL-
1β and in vivo in freshly isolated AEC by LPS+MV, and is less in P2X7R
-/-
. Secondly, the 
shedding of VCAM-1 from AEC surface is increased by IL-1β and was blocked in 
presence of metalloproteinase inhibitor. Third, there was concomitant increase of 
ADAM-17 activity in AEC I by LPS+MV and is reduced in P2X7R
-/-
 mice. Fourthly, 
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BzATP stimulation increases the ADAM-17 activity in HEK-P2X7R cells, indicating 
ADAM-17 activation is mediated by P2X7R in AECI. 
In summary, our experimental results demonstrate a direct link between P2X7R and 
control of neutrophil migration into injured lung tissue. This occurs via a previously 
unrecognized mechanism by which P2X7R on AEC I regulate the flux of neutrophils 
through shedding of VCAM-1 into local alveolar microenvironments by cellular 
activation of ADAM-17 (Figure 3.9). Previously, P2X7R has been demonstrated to be the 
major regulatory system for mature IL-1β release from alveolar macrophage (Myrtek et 
al., 2008); these new data add to the pleiotropic properties of P2X7R, demonstrating that 
P2X7R-bearing AEC I can contribute acute lung injury. Furthermore, these new data 
indicate a prime role for P2X7R in modulating the expression of VCAM-1 receptors on 
the surface of AEC I. Thus, P2X7R resides at the critical nexus of cytokine regulation, 
neutrophil recruitment and inflammation as a vital regulator of alveolar function. 
Targeting P2X7R and VCAM-1 may provide a new therapeutic strategy to reduce 
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SUMMARY AND CONCLUSION 
 
 AEC I play important roles in alveolar barrier protection and fluid homeostasis. 
Earlier studies indicated that purinergic P2X7 receptors were specifically expressed in 
AEC I. However, their implication in lung functions has not been studied. The present 
study was hence designed to study the pathophysiological role of P2X7 receptor in  
AEC I.  
 We studied the AEC I and AEC II communications as they relate to surfactant 
secretion. Our results indicated that P2X7 receptors are functionally active in AEC I. The 
stimulation of P2X7 receptors in AEC I releases soluble mediator, ATP, which acts in a 
paracrine fashion on AEC II. Activation of P2Y2 receptors by extracellular ATP 
increases surfactant secretion from AEC II via a PKC–dependent signaling pathway. 
Moreover, the paracrine regulation of surfactant exocytosis by P2X7 receptor is a 
physiologically relevant phenomenon as the P2X7 receptor knock-out mice are less 
responsive to hyperventilation-induced surfactant release. We conclude that P2X7 
receptors in AEC I are an important regulator of surfactant secretion and AEC I and AEC 
II communications.  
 Next, we explored the pathological function of P2X7 receptor in AEC I. We 
compared the P2X7 receptor knock-out and wild-type mice for their susceptibility to 
ALI. Our results identified that P2X7 receptor knock-out mice are less susceptible to LPS 
and mechanical ventilation-induced ALI. Furthermore, delving into the mechanism, we 
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found that P2X7 receptor-mediated sVCAM-1 release from AEC I is crucial for the 
recruitment of neutrophils in the alveolar space. Moreover, the metalloprotease, 
ADAM17 are responsible for VCAM-1 shedding from AEC I surface. 
 In summary, we for the first time implicated the roles of P2X7 receptors in 
surfactant regulation and neutrophil infiltrations in ALI. Thus, P2X7R resides at the 
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